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Abstract:
Pancreatic cancer is a lethal disease and is frequently associated with a KRAS gene mutation.
Due to a very high frequency of gain-of-function mutations within the KRAS gene, and its
proven role in initiation of pancreatic cancer in animal models, mutant KRAS is considered a
rational therapeutic target. To determine the potential role of oncogenic KRAS in pancreatic
tumor maintenance in vivo, we generated a mouse model with a Doxycycline regulated
expression of oncogenic KRAS (KRASG12D) in the pancreas. Using this reversible model, we
demonstrated that the expression of oncogenic KRAS in a Cdkn2a deficient background was
sufficient to induce invasive pancreatic cancer with distant metastasis that regressed
completely upon ablation of oncogenic KRAS in both primary and tumor-transplanted
recipient mice. This finding suggests that the expression of oncogenic KRAS is required for
the maintenance of pancreatic cancer, and provides a strong rationale for using KRAS
targeted therapies in the treatment of pancreatic cancer.
Despite the complete macroscopic remission of invasive tumors upon downregulation
of oncogenic KRAS, a few cancer cells survived and remained dormant for a protracted
period of time, and these cells were responsible for the rapid recurrence upon KRAS
reactivation. Genome-wide transcriptome analysis of in vivo-derived bulk and residual cancer
cells lacking expression of oncogenic KRAS identified an increase in autocrine IGF-1/AKT
signaling in residual cancer cells. We also identified IGF1 signaling as a common survival
mechanism of residual cancer cells in a c-MYC-driven pancreatic tumor model.
Pharmacological inhibition of IGF-1R signaling significantly delayed the tumor recurrence in
both the tumor models, suggesting a crucial role of IGF-1R signaling in the survival of cancer

cells in the absence of oncogenic drivers. Findings from animal models were validated in
human cancer pancreatic cells harboring KRAS mutations by demonstrating a compensatory
increase in IGF1 signaling in response to a conditional knockdown of KRAS. The collective
results from our study suggest that residual cancer cells can survive in the absence of tumor
driving oncogenes by an upregulation of the autocrine IGF1 signaling loop. Co-targeting
oncogenic drivers and IGF-1R signaling might be an effective strategy for eliminating
minimal residual disease in pancreatic cancer.
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Chapter 1: Introduction*
*A part of this chapter is derived from previously published original article:
Lin WC, and Rajbhandari N, Liu C, Sakamoto K, Zhang Q, Triplett AA, Batra SK, Opavsky R,
Felsher DW, Dimaio DJ, Hollingsworth MA, Morris JP, Hebrok M, Witkiewicz AK, Brody JR,
Rui H, Wagner KU (2013). Dormant Cancer Cells Contribute to Residual Disease in a Model
of Reversible Pancreatic Cancer. Cancer Research 73, 1821-1830. PMID: 23467612
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1.1. The Overview of pancreatic cancer
1.1.1. Epidemiology
Pancreatic cancer is one the most lethal type of cancer in the western world. It ranks 4th among
cancer related deaths in United States and 6th in Europe (Michaud, 2004). An estimated 48,900
new cases of pancreatic cancer was expected to occur in US in 2015. The mortality rate due to
this disease is so high that over 40,500 patients were expected to die in year 2015 in US only
(2015 Cancer Facts & Figures of American Cancer Society). Pancreatic cancer is also one of the
few cancers for which 5-year survival rate has not improved significantly since last 40 years. It
has been estimated that at current pace, pancreatic cancer will become the second leading cause
of cancer related death in 2030 (Rahib et al., 2014).
The exact causes of pancreatic cancer are still not understood, however, variation in the
rates and time trends across the world suggests that environmental factors likely play a significant
role in its pathogenesis (Michaud, 2004). Several risk factors associated with increased pancreatic
cancer risk have been identified. Cigarette smoking is the strongest known modifiable risk factor
of pancreatic cancer. Cigarette smoking is predicted to double the pancreatic cancer risk (Bosetti
et al., 2012; Meyer et al., 2015). Approximately, 20% of the pancreatic cancer cases are supposed
to be caused by cigarette smoking. Numbers of studies have reported a reduction in pancreatic
cancer risk within decade of quitting smoking (Bosetti et al., 2012; Zou et al., 2014). Age has
been proposed to be another strong risk factor of pancreatic cancer, as the risk of developing
pancreatic cancer increases with age (Lowenfels and Maisonneuve, 2004, 2006). Pancreatic
cancer is rarely detected before the age of 40. Over 80% of pancreatic cancers are only diagnosed
at the age of 60 to 80 years (Lowenfels and Maisonneuve, 2006). Many other factors like chronic
pancreatitis, diabetes mellitus, obesity, diets rich in fats and alcohol consumption have been
linked to pancreatic cancer (Batty et al., 2009; Lowenfels and Maisonneuve, 2004, 2006). Besides
these above-mentioned environmental factors, genetic alterations can also cause cancer of the
exocrine pancreas. Approximately 10% of the pancreatic cancer is caused due to a genetic
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abnormality or familial predisposition. A few examples of genetic abnormalities that increase the
risk of pancreatic cancer include, hereditary breast and ovarian cancer syndrome caused by
BRCA2 gene mutation, familial melanoma by mutation in p16/CDKN2A gene, familial
pancreatitis caused by mutation in PRSS1 gene, Lynch syndrome caused by defect in genes
MLH1 or MSH2 and Peutz-Jeghers syndrome caused by a defect in STK11 gene (Jaffee et al.,
2002). (Detailed information regarding the causes, risk factors and prevention of pancreatic
cancer

can

be

found

in

the

official

webpage

of

American

Cancer

Society

at

http://www.cancer.org/cancer/pancreaticcancer/detailedguide/pancreatic-cancer-risk-factors).
1.1.2. Pathology
The pancreas (derived from the greek words, “pan” meaning “all” and “creas” meaning “flesh”)
is an elongated, tapered glandular organ located in the left side of the abdomen behind the
stomach. The pancreas is an unique organ which is comprised of both exocrine gland, which
secretes and empties digestive enzymes (chymotrypsinogen, trypsinogen, amylase and pancreatic
lipase) into the small intestine, and an endocrine gland, also commonly known as Islets of
Langerhans, which is responsible for secretion of 3 major hormones into the circulation, namelyglucagon, insulin and somatostatin.

1.1.2.1. Neoplasms of Pancreas
As the pancreas is comprised of different varieties of cells in the endocrine and exocrine
pancreas, a diversity of different types of neoplasms can arise in the pancreas, essentially from
any cell types, such as ductal adenocarcinoma and pancreatic neuroendocrine tumor. It is
extremely important to recognize the type of the pancreatic tumor as every tumor is treated
differently, and is associated with different prognoses. Essentially, pancreatic neoplasia can be
broadly classified into 2 main categories: (i) Exocrine neoplasia and (ii) Endocrine neoplasia.

3

1.1.2.1.1. Neoplasms of the exocrine pancreas
Pancreatic ductal adenocarcinoma (PDAC) and its other variants are the most common pancreatic
neoplasms, representing over 85% of all the pancreatic neoplasms, hence PDAC and pancreatic
cancers are often synonymously used (Klöppel et al., 2000). World Health Organization (WHO)
defines PDAC as- any carcinoma occurring almost exclusively in adults that probably arises from
and is phenotypically similar to, pancreatic duct epithelia (Fig 1.1 A), with mucin production and
expression of a characteristic cytokeratin pattern is called ductal adenocarcinoma of pancreas (Fig
1.2 A).
Three major non-invasive precursor lesions of PDAC have been identified. These are: (1)
pancreatic intraepithelial neoplasia (PanIN), (2) intraductal papillary neoplasm (IPMN), and (3)
mucinous cystic neoplasm (MCN) (Hruban et al., 2008; Hruban et al., 2007).
PanINs are non-invasive microscopic precursor lesions in the smaller pancreatic ducts
(<5 mm). PanINs can be papillary or flat. They are composed of columnar to cuboidal cells with
varying amount of mucins. PanINs are sub-classified into 3 categories: (a) PanIN-1, (b) PanIN-2,
and (c) PanIN-3 lesions, depending upon the degree of cytologic and architectural atypia (Hruban
et al., 2004). Histologically, PanIN-1s are flat epithelial lesions composed of tall columnar cells
with basally located nuclei and abundant supra-nuclear mucins. PanIN-1 lesions are further
classified into subcategories: PanIN-1A and PanIN-1B. The nuclei in PanIN-1A are small and
round to oval in shape. When oval the nuclei are oriented perpendicular to the basement
membrane (Fig 1.1 B). PanIN-2s are histologically distinct from PanIN-1, as these lesions
demonstrate some nuclear abnormalities like some loss of polarity, nuclear crowding, enlarged
nuclei, pseudo-stratification and hyper-chromatism. Cribriforming luminal necrosis and marked
cytologic abnormalities are generally not seen. Presence of cribriforming luminal necrosis
suggests the diagnosis of higher grade PanINs (Fig 1.1 D). Likewise, PanIN-3 lesions are mostly
papillary or micro-papillary with some occasional exceptions. True cribriforming, budding-off of
small clusters of epithelial cells into the lumen and luminal necrosis should all suggest the
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diagnosis of PanIN-3. These lesions can be distinguished from lower-grade PanINs by a loss of
nuclear polarity, dystrophic goblet cells, mitoses which may occasionally be abnormal, nuclear
irregularities and prominent nucleoli (Fig 1.1 E).
IPMNs are a less common form of precursor lesions of PDACs. IPMNs are intra-ductal
papillary mucin-producing epithelial neoplasms, arising in the main pancreatic duct or its major
branches. They are larger than PanINs and therefore usually visible grossly or by radiologic
imaging. IPMNs may extend into small ducts (Hruban et al., 2004). IPMNs are further divided
into benign, borderline and malignant non-invasive or invasive lesions (Fig 1.1 F).
Likewise, MCNs are another rare and slow-growing form of ductal pre-neoplastic lesions
(Testini et al., 2010). These are cystic epithelial neoplasms occurring almost exclusively in
women with no obvious communication with the pancreatic ductal system and composed of
columnar mucin-producing epithelium, which is supported by ovarian-type stroma. These
distinguishing features along with its usual larger size allow MCNs to be readily distinguished
from PanINs. MCNs can also be further subdivided into adenoma, borderline and malignant noninvasive or invasive neoplasia (Klöppel et al., 2000).
Acinar cell carcinoma is a rare form of the exocrine pancreatic cancers, representing less
than 2% of all the neoplasms of the exocrine pancreas despite the fact that acinar cells represent
the major proportion of the pancreas. It is characterized by the presence of relatively uniform
neoplastic cells that are arranged in solid and acinar patterns, and produce excessive amount of
pancreatic enzymes like lipase. Microscopically, cancer cells in ACC show an accumulation of
large amount of characteristic granules in the cytoplasm, which represents the zymogen granules
within the cells. ACC generally exists in two architectural patterns: (1) acinar, where the
cancerous cells form thin lumen with basally located nucleus and moderate amount of
eosinophilic granular cytoplasm in apical portion, and (2) solid, where the cells are arranged in
sheets and nests without any evident lumen (Fig 1.2 B). Basally palisaded nucleus can be
observed at the interface of solid nests and stroma (Klimstra, 2007; Klöppel et al., 2000).
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1.1.2.1.2. Neoplasms of endocrine pancreas
Pancreatic endocrine tumor (PET), also called Islet cell tumor or neuroendocrine tumor (NET) of
the pancreas is a very rare type of cancer, clinically detected in 1:100,000 persons. It comprises
less than 2% of all pancreatic tumors (Metz and Jensen, 2008). The histologic appearance of PET
is highly variable with neoplastic cells arranged in nesting (Fig 1.2 C) or glandular pattern
(Klimstra, 2007). The exact molecular mechanism of PET is unknown, however, individuals with
four inherited disorders have increased incidence of PETs: Multiple Endocrine Neoplasia-type 1
(MEN1; caused by mutation in MEN1 gene on chromosome 11q13), von Hippel-Lindau disease
(VHL; caused by mutation in VHL gene on chromosome 3), von Recklinghausen’s disease (VRD
or neurofibromatosis 1[NF1]; caused by mutation in NF1 gene on chromosome 17) and tuberous
sclerosis complex (TSC; caused by mutation in 2 genes, TSC1 and TSC2 on chromosome 9
(Alexakis et al., 2004; Jensen et al., 2008; Metz and Jensen, 2008). MEN1 is the most common as
the penetrance of this disease is very high for PET development. PET is not a single disease but
comprises broad range of neoplasms of endocrine cells of pancreas, for example, Insulinomas
(insulin secreting tumors), gastrinomas, also called Zollinger-Ellison Syndrome (gastrin secreting
tumor), glucagonomas (glucagon secreting tumors), VIPomas (vasoactive intestinal polypeptide
[VIP] secreting tumors), somatostatinomas (somatostatin secreting tumors) and GRFomas
(growth

hormone-releasing

factor

[GRF]

(http://pathology.jhu.edu/pc/treatmentendocrine.php?area=tr).
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secreting

tumors)

Figure 1.1. Normal duct and pre-neoplastic ductal lesions in human pancreas: (A)
Normal duct surrounded by acinar cells. (B) PanIN-1A lesion with cuboidal to columnar
transformed ductal epithelial cells. (C) PanIN-1B lesion with pseudo-stratified ductal
epithelium. (D) PanIN-2 lesion with hyperplasia and loss of polarity. (E) PanIN-3 lesion
with loss hyperplasia and budding epithelium into lumen of duct. (F) IPMN lesions. All
the images are reprinted with permission from The Sol Goldman Pancreatic Cancer
Research Center, Johns Hopkins Medicine’s webpage.
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Figure 1.1.
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Figure 1.2. Histological features of invasive primary tumors of human pancreas: (A)
Adenocarcinoma with nerves wrapped within ductal lesion. (B) Acinar cell carcinoma with
typical compact, granular and eosinophilic cytoplasm. (C) Pancreatic neuroendocrine tumor.
Images (A) and (B) are reprinted with permission from The Sol Goldman Pancreatic Cancer
Research Center, Johns Hopkins Medicine’s webpage. Image in (C) Macmillan Publishers Ltd:
[Modern Pathology] (Klimstra, 2007)
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Figure 1.2.
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1.1.3. Molecular genetics of pancreatic cancer
Pancreatic cancer is one of the deadliest types of human cancer in United States and western
world. The pancreas is an extremely common site for the development of early pre-neoplastic
lesions, that in a few cases progresses to invasive adenocarcinoma by acquiring series of genetic
changes in various tumor susceptibility loci (Hruban et al., 2000; Maitra and Hruban, 2008). This
section discusses the various genetic alterations that are frequently encountered in human
pancreatic cancer, and are known to play a significant role in tumor pathogenesis and progression.

1.1.3.1. KRAS
KRAS (Kirsten rat sarcoma viral oncogene homolog) is a small GTPase of the RAS gene family,
which mediates a range of cellular functions including proliferation, survival and differentiation.
The active KRAS protein is bound to GTP. Its inactivation occurs via GTPase activating proteins
(GAPs), which promote GTP hydrolysis to GDP ensuing in the inactivation of KRAS signaling.
Constitutive activation of KRAS results due to point mutation at codon 12 or occasionally at
codon 13 or 61 (Malumbres and Barbacid, 2003). Activating mutations in KRAS are the most
common genetic abnormality in human pancreatic cancer accounting for more than 70% of the
cases (COSMIC database). The very high mutation frequency of KRAS in human pancreatic
cancer suggests its role in cancer initiation. This idea is supported by the findings of identical
KRAS gene mutation in both PanIN-1 lesions and adenocarcinoma of the same patients (Lemoine
et al., 1992; Maitra and Hruban, 2008). This hypothesis is now strongly corroborated by the
application of genetically engineered mouse models (GEMM) for the expression of mutant allele
of Kras (KRASG12D) exclusively in the mouse pancreas (Aguirre et al., 2003; Hingorani et al.,
2003). These mice developed an entire progression of PDAC from pre-invasive neoplasia to
invasive and metastatic disease, verifying the hypothesis that oncogenic KRAS is sufficient to
induce pancreatic cancer at least in mice.
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1.1.3.2. MYC
The c-MYC (Myelocytomatosis oncogene) is a cellular homolog of the retroviral MYC protein. It
belongs to the MYC transcription factor family, which also includes N-MYC and L-MYC. It was
first identified at the breakpoint of a fusion chromosome in human Burkitt’s lymphoma (DallaFavera et al., 1982; Taub et al., 1982). Yamada and coworkers were the first to point towards the
possible connection between c-Myc and human PDACs when they demonstrated a nearly 50-fold
amplification of this gene in primary as well as lymph node metastasis of PDACs (Yamada et al.,
1986). Many other subsequent studies later demonstrated amplification and upregulation of this
oncogene in a large proportion of human pancreatic cancers ranging from 30 to 70% of all cases
(Han et al., 2002; Mahlamaki et al., 1997; Schleger et al., 2000).
The c-MYC protein is also regulated post-translationally by phosphorylation at two
critical sites i.e., threonine 58 (T58) and serine 62 (S62) within its MYC Box I (MB-I) domain.
The phosphorylation of c-MYC at T58 by glycogen synthase kinase-3 (GSK3) results in
degradation of the c-MYC protein (Gregory et al., 2003). However, PI3K/AKT mediated
phosphorylation and inhibition of GSK3 subsequently prevents degradation of c-MYC, resulting
in its accumulation (Asano et al., 2004). At the same time, RAS-MAPK pathway mediated
phosphorylation of c-MYC at S62 results in its subsequent stabilization (Sears et al., 1999; Sears
et al., 2000). These observations strongly indicate that c-MYC might be upregulated in many
cancers, including pancreatic cancers, by mechanisms other than gene amplification. Increased
expression of c-MYC in PDACs, as well the early pre-neoplastic lesions in the KRAS-induced
murine tumor model also suggest that c-MYC acts downstream of mutant KRAS, and plays an
important role during pancreatic cancer pathogenesis (Lin et al., 2013).
In a seminal study, we have recently provided the first direct evidence for the role of cMYC in PDAC pathogenesis, where we demonstrated that overexpression of c-MYC alone in
mouse pancreatic progenitor cells (Fig 1.3 A) was sufficient to induce classical PanIN lesions
(Fig 1.3 B[i]), which later progressed to primary and metastatic PDACs (Fig 1.3 B[ii]). In
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addition to that, we also demonstrated that tumor cells at both primary and metastatic sites (Fig
1.3 B[iii & iv]) were dependent upon the expression of c-MYC for their survival. This was
indicated by the complete macroscopic regression of advanced-stage pancreatic tumors by
induction of massive tumor-cell death upon ablation of oncogenic c-MYC (Fig 1.3 C). In the
same study, using an elegant tumor transplantation approach where we transplanted GFP-labeled
tumor cells into the pancreas of wild-type recipient mice, we also demonstrated that despite the
complete visible shrinkage of tumors upon down-regulation of c-MYC, a few cancer cells could
still survive (Fig 1.4 A and B), remain dormant (Fig 1.4 B) and cause rapid tumor relapse upon
re-induction of c-MYC irrespective of the loss of Cdkn2a (Fig 1.4 C). In brief, our work
highlighted a very essential concept that despite very high potential of targeted therapy in the
treatment of pancreatic cancer, a few cancer cells might be able to survive the targeting of the
driving-oncogenes and result in tumor relapse.

1.1.3.3. CDKN2A (INK4A/ARF)
Cyclin-dependent kinase inhibitor 2A (CDKN2A) tumor suppressor locus encodes two
structurally unrelated tumor suppressor proteins by alternative splicing, namely p16-Inhibitor of
cyclin-dependent kinase 4a (p16INK4A) and alternative reading frame (ARF) (D'Amico et al., 2004;
Quelle et al., 1995). The INK4A/ARF locus is involved in the regulation of the retinoblastoma
(RB) and p53 tumor suppressor pathways. p16INK4A is a regulator of the cyclin-dependent kinase
4/6 (CDK4/6) mediated phosphorylation of the retinoblastoma protein (Rb), thereby releasing the
E2F transcription factor, which enhances the cell cycle progression through the G1/S checkpoint.
On the other hand, p19ARF (p14ARF in human) is a negative regulator of mouse double minute 2
(MDM2), which inhibits the MDM2-mediated degradation of the p53 tumor suppressor protein.
Loss of function of p16INK4A via mutation, deletion or promoter hyper-methylation is the
most frequent gene inactivation event in the majority of human pancreatic cancer cases.
Inactivation of the p16 tumor suppressor appears to occur in the later stages of tumor progression,
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as they are more frequently detected in high-grade PanINs (Hansel et al., 2003; Hruban et al.,
2000). Although mutations in p14ARF alone has not been reported in human PDACs, a proportion
of PDACs exhibit a homozygous loss of both p16INK4A and p14ARF, indicating the possible
pathogenetic role of p14ARF in human pancreatic cancer (Hustinx et al., 2005; Rozenblum et al.,
1997). According to the currently accepted tumor progression model for pancreatic cancer, the
role of CDKN2A in PDAC highlights its importance during tumor progression rather than tumor
initiation (Hruban et al., 2000), which is supported by the fact that individuals with a germline
mutation in p16INK4A rarely develop pancreatic cancer unless they acquire other genetic events.
This idea is strongly substantiated by the accelerated formation of high-grade PanINs and PDAC
in genetically engineered mouse models with bi-allelic deletion of the Cdkn2a gene along with
concomitant expression of oncogenic Kras (Aguirre et al., 2003). Collectively, these observations
support the notion that Cdkn2a locus plays an important role in the progression of pancreatic
cancer.

1.1.3.4. TRP53
The TRP53 gene encodes for the tumor suppressor p53 protein, which is a transcription factor that
functions in a homo-tetrameric complex and plays an important role in the cell, such as regulation
of G1/S cell cycle checkpoint, maintenance of G2-M arrest, apoptosis and senescence in response
to wide variety of cellular stress stimuli such as DNA-damage, oncogene expression or hypoxia
(Maitra and Hruban, 2008). Inactivation of TRP53 gene is seen in over 50% of pancreatic cancers
and occurs predominantly via a single allelic loss in combination with an intragenic mutation of
the second allele (Hansel et al., 2003). TRP53 gene mutations generally result in missense
alterations of the DNA-binding domain in more than 50% of PDACs (Rozenblum et al., 1997).
Similar to CDKN2A, loss of TRP53 tumor suppressor gene occur late in the development of
pancreatic cancer (Hruban et al., 2000) insinuating the role of TP53 as a critical barrier in
malignant progression rather than tumor initiation itself. Experimental validation of the role of the
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p53 tumor suppressor as a preventive barrier in PDAC progression has come from the use of
GEMM, as the pancreas-specific ablation of Trp53 has been shown to significantly shorten the
tumor latency due to the oncogenic KRAS (KRASG12D) in mice (Bardeesy et al., 2006a). Despite
the inactivation and loss of function of the p53 as a tumor suppressor, it has been suggested to
acquire a gain-of-function by the mutation during the tumor progression (Oren and Rotter, 2010).
This hypothesis is strongly validated by the observation of significantly increased metastasis of
the tumor cells to distant organs due to the pancreas-specific expression of mutant form of the
p53 (p53R172H, an ortholog of the most common p53 mutation in human PDAC) in combination
with the oncogenic form of KRAS in another model of genetically engineered mice (Hingorani et
al., 2005). Together, these findings from human pancreatic cancers and the GEMMs, strongly
suggest that p53 plays a critical role in impeding the progression of PDAC. More importantly,
p53 cooperates with oncogenic KRAS to enhance the tumor progression by acquiring a gain-offunction mutation rather than the complete loss of TRP53 alleles in a majority of human
pancreatic cancers.

1.1.3.5. SMAD4/DPC4
SMAD4, also known as deleted in pancreatic cancer 4 (DPC4) was originally isolated from
human chromosome 18q21.1 in pancreatic cancer. SMAD4 is a genuine tumor suppressor and
transcriptional regulator that serves as a central component of the transforming growth factor
β (TGFΒ) pathway. Inactivating mutations in SMAD4 are highly common in pancreatic cancer as
compared to any other cancers. Over 50% of pancreatic cancers bear deletion or mutations in
SMAD4 (Hahn et al., 1996; Hansel et al., 2003). Such a high frequency of SMAD4 gene
alterations is strongly indicative of the potential role of SMAD4 in pancreatic tumors. Unlike the
activation mutation in the KRAS gene, inactivation or loss of SMAD4 expression occurs only in
the late stage of the pancreatic neoplastic progression, at the stage of PanIN-3 or invasive
carcinoma (Wilentz et al., 2000). The protective role of the tumor suppressor SMAD4 in
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pancreatic cancer progression has been experimentally validated using GEMM that expresses a
the mutant Kras allele with concomitant deletion of Smad4. SMAD4 deficiency significantly
accelerated the formation of pancreatic intraepithelial neoplasia and invasive PDAC due to
oncogenic KRAS (KRASG12D) in mice, hence providing genetic confirmation that SMAD4 is a
tumor suppressor in PDAC (Bardeesy et al., 2006b; Kojima et al., 2007).
Besides these above-mentioned genes, human pancreatic cancer is associated with many
other less frequent genetic alterations implicated in its pathogenesis, which include a range of
oncogenes like AKT2, MYB, EGFR and ERBB2, as well as a set of tumor suppressor genes like
BRCA2, ALK4, TGFBR1 and TGFBR2 (Bardeesy and DePinho, 2002; Hansel et al., 2003).
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Figure 1.3. c-MYC is required for initiation and maintenance of pancreatic ductal
adenocarcinoma in mice: (A) Genetically engineered mouse model based on three essential
transgenes: Pdx1-Cre, CAG-tTA and TetO-driven responder genes (c-MYC [Myc] and
Luciferase [Luc]), which allows for spatial and temporal regulation of the expression of
oncogenic c-MYC in the exocrine pancreas. The expression of transgenes under the control of
TetO promoter (c-MYC) is turned-off by treatment of transgenic mice by Doxycycline (Dox) and
the inhibition can be reversed by withdrawal of Dox. The use of CAG-GFP permanently labels
normal and cancerous cells, which allows for easy detection in distant metastatic organs, as well
as in the pancreas of wild-type recipient mice. (B) Overexpression of c-MYC in mouse pancreas
results in formation of PanIN lesions (I) that progress to invasive ductal adenocarcinoma (II) with
frequent metastases to distant organs like liver (III) and lung (IV). Bar represents 50um. (C) H&E
stained section (top panel) from Pdx1-Cre/CAG-tTA/TetO-MYC mice showing regression of
tumor on downregulation of c-MYC (+Dox) for 7 days (right) as compared to untreated control
tumor (-Dox). Tumors shrink by undergoing massive cell death upon downregulation of c-MYC
(+Dox), as indicated by increased TUNEL staining (green; lower panel) in comparison to c-MYC
expressing control tumors (-Dox). Bar represents 20 µm.
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Figure 1.3.

18

Figure 1.4. Downregulation of oncogenic c-MYC results in tumor regression, but with
residual disease in mice: (A) Orthotopic transplantation of genetically labeled tumor cells
allowed detection of the rare GFP positive (green) residual cancer cells persisting in regressed
tumors after downregulation of c-MYC for 8 days (+Dox; right) with great sensitivity. Images on
the left represent GFP-positive pancreatic tumors from recipient mice with persistent expression
of c-MYC (-Dox) (B) (Top panel) Immunofluorescence staining showing GFP positive (green)
residual cancer cells, which survived even after complete ablation of c-MYC (red) [+Dox; right].
(Middle panel) Residual cancer cells in regressed tumor resisted death and remained dormant in
the absence of c-MYC (+Dox) as indicated by the absence of Ki-67 (red) staining in GFP positive
cancer cells (green) and (bottom panel) the absence of TUNEL (green) staining in the residual
cancer cells (red). All images on the left panel represent the c-MYC expressing (-Dox) tumors,
shown for the direct comparison of residual tumor. Arrows indicate GFP-positive residual cancer
cells without c-MYC, Ki67 and TUNEL staining in top, middle and bottom panels respectively.
“N” represents normal tissue, and “T” represents tumor tissue. Bar represents 25um. (C) Tumor
growth chart shows, big palpable pancreatic tumors in individual recipient mice completely
shrunk to a non-palpable state within 8 days of Dox treatment (+Dox; c-MYC downregulation),
which however, swiftly reappeared after withdrawal of Dox (-Dox; c-MYC re-induction)
regardless of Cdkn2a status.
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Figure 1.4.
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1.2. The biology of RAS gene family
1.2.1. Historical development
The acronym RAS is derived from the two words “rat” and “sarcoma”, as Ras genes were first
identified as the responsible genetic factor for the transforming behavior of the Harvey and
Kirsten strains of rat sarcoma virus. The RAS gene is a prototypical member of the RAS
superfamily of proteins, which belongs to a class of protein family called small GTPases. RAS
proteins are ubiquitously expressed in all cells of eukaryotes and are involved signal transduction
from outside of the cell to inside of the cell. The mammalian RAS family consists of 3 genes:
HRAS (Harvey rat sarcoma viral oncogene homolog), KRAS (Kirsten rat sarcoma viral oncogene
homolog) and NRAS (Neuroblastoma RAS viral oncogene homolog).
The history of the RAS research can be traced back to the mid-sixties of the twentieth
century when Jennifer Harvey first reported that leukemia virus extracts from leukemic rats were
able to induce sarcoma in new-born rodents. This oncogenic virus was later named after her as
Harvey rat sarcoma virus (Ha-RSV). Next in 1967, Werner Kirsten isolated and identified another
retrovirus from mice capable of causing malignant lymphoma in Wister-Furth rats, which was
afterwards named after him, Kirsten murine sarcoma virus (Ki-MSV). However, it was only in
early 1970s when first, Edward Scolnick and his colleagues, and few years later Gareth Anderson
and Keith Robbins at National Cancer Institute (NCI) demonstrated through an RNA-DNA
hybridization technique that the Ha-RSV and Ki-RSV were in fact recombinant viruses which
had hijacked the cellular gene from the rat genome. Subsequently, in the early 1980s cellular
homologues of both viral Harvey and Kirsten RAS sequences were identified in the rat genome
followed by its subsequent discovery in mouse and human genomes.
Despite the wealth of knowledge regarding the transforming ability of RAS oncogenes in
mice and rats, the role of RAS in humans was largely ignored until the early 1980s. However,
after years of gene transfer and subsequent cloning experiments, the breakthrough came in year
1982 when the labs of Geoffrey Cooper, Robert Weinberg and Mariano Barbacid, all at the same
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time reported that the transforming genes of human bladder cancer cells (T24 and EJ) and lung
cancer cells (LX-1) were homologous to RAS genes of Harvey and Kirsten sarcoma viruses. The
findings from different independent studies provided the evidence for the existence of
transforming genes in human cancers, and firmly established RAS as the first human oncogene.
Later, in the same year, a series of restriction digestion and detailed sequence analysis of
transforming RAS genes from T24 and EJ human bladder cancer cells revealed that the oncogenic
RAS (HRAS in this case) varied from its normal cellular counterpart by a single point mutation
resulting in a constitutive activation of the oncogene. Afterwards, the identification of a point
mutation in the KRAS oncogene in a tumor biopsy from a lung cancer patients in contrast to the
normal cells further reassured the claim that mutation in the RAS oncogene was not a laboratory
artifact but a common phenomenon for its activation during oncogenesis. Besides HRAS and
KRAS, an additional, third transforming human RAS gene was subsequently identified in a
neuroblastoma cell line and was named NRAS. This RAS gene was not identified in any
retroviruses previously.
RAS proteins were initially assumed to function like hetero-trimeric G-proteins, as both
could shuttle between inactive and active states by binding with GDP and GTP respectively,
having intrinsic GTP hydrolyzing activity. This assumption was based on the observation made
by Edward Scolnick’s group where they found a very high-affinity binding of GTP to rat derived
viral H-RAS (vi-Hras) proteins. The first biochemical evidence suggesting that the RAS proteins
were in fact GTPases, was provided by 3 independent research groups, where scientists observed
that the mutated RAS proteins were functionally different, with impaired GTPase activity, from
their normal counterparts. This observation along with the sequence/structural homology between
the alpha subunit of G-proteins and the localization of the vi-RAS proteins in the inner side of the
plasma membrane strongly suggested towards the idea that the RAS proteins were signal
transducers which would transmit messages from outside of the cell to the inside of the cells. The
first evidence that RAS serves as a signal transducer for growth factors was presented by Kamata
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and Feramisco where they demonstrated that EGF treatment of rat kidney cells transformed with
Harvey murine sarcoma virus (Ha-MSV) significantly stimulated GTP binding to RAS proteins.
However, Stacey and coworkers were the first to provide the biochemical evidence that Ras was
in fact a signal transducer for mitogens by using the Ras protein specific monoclonal antibody to
block the activity of Ras. In their experiment, direct inhibition of Ras by microinjection of the
RAS-specific neutralizing antibody (Y13-259) into the NIH 3T3 cells resulted in the inhibition of
serum induced DNA synthesis suggesting that Ras was an essential mediator in transmitting the
signals from outside of the cell to inside upon growth factor stimulation. Using a similar
approach, subsequent work by the same group revealed that RAS activity was also essential for
the transformation induced by oncogenes derived from growth-factor receptors or plasma
membrane associated tyrosine kinases (SRC, FMS and FES), but not by serine/threonine kinases
residing in the cytoplasm (RAF and MOS). The same group further demonstrated the importance
of the RAS proteins as essential transducers to other growth factors that signaled through receptor
tyrosine kinases (Insulin, EGF and PDGF) in subsequent years. They used a different approach of
blocking the cellular RAS by injecting dominant inhibitory RAS proteins (RASS17N) in a very
similar way as the neutralizing antibody against RAS. These findings led to an extremely
important foundation for the current understanding of the mechanism of growth factor signaling,
or the flow of information from the outside to the inside of the cells. (See Fig 1.5 for progressive
timeline of RAS research).
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Figure 1.5. Chronicle of key discoveries in the field of RAS research: Timeline showing key
events in the field of RAS research [For detailed information and references regarding the
discovery, see reviews by Malumbres and Barbacid (2003), Karnoub and Weinberg (2007), and
Cox and Der (2010).]
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1.2.2. Structure of RAS isoforms
The mammalian RAS gene family consists of 3 canonical members, namely HRAS, NRAS and
KRAS. These 3 loci encode 4 different, ubiquitously expressed protein isoforms, HRAS, NRAS,
KRAS-4A and KRAS-4B. The latter 2 isoforms arise from the alternative splicing of the 4th exon
of the KRAS locus. All of the 4 isoforms of RAS proteins are highly homologous regarding their
sequence similarity and primary structure (>80% homology) with the sequence length of 189
amino acids except for the KRAS-4B isoform, which is 188 amino acids long (Fig 1.6).
Abraham de Vos and colleagues were the first to solve three dimensional crystal structure
of the RAS protein (HRAS) without its C-terminal hypervariable region. They noted that the
normal human HRAS lacking its flexible C-terminal 18 residues consisted of 6 stranded betasheets, four α-helices and nine connecting loops (de Vos et al., 1988). However, the structure of
the G-domain proposed a year later by Wittinghofer and colleagues was more accurate suggesting
the presence of 6 β-strands and 5 α-helices (Pai et al., 1989). The original structure by de Vos’s
group was later revised accordingly (Tong et al., 1989).
Basically, all the RAS family members can be divided into 2 distinct domains: (1) The Gdomain and (2) Hypervariable domain/region (HVR). The core G-domain is comprised of five
conserved guanine nucleotide consensus sequence elements which spans 166 amino acids from
the N-terminus, binds guanosine nucleotides and Magnesium, and is highly conserved across all
the RAS superfamily members (90% homology). The G domain contains five G motifs that bind
GDP/GTP directly. The first 85 amino acids are 100% identical in all four proteins and specify
the binding of GDP and GTP (Santos, 2011). G1 or the P-loop (Phosphate-binding loop, amino
acids 10 to16) is the glycine-rich loop (GXXXXGKS/T), which binds the γ-phosphate of GTP via
the nitrogen atom of lysine-16 residue. The hydroxyl group of serine or threonine interacts with
the β-phosphate oxygen and the magnesium ion. G2, also called switch I (amino acids 32-38),
consists of Threonine-35 that binds the terminal phosphate (γ-phosphate) of GTP. G2 (switch I) in
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combination with G3, also called Switch II (amino acids 59-67) regulate binding of RAS
regulators and effectors. G3 has the DXXG motif, where the Aspartate-57 is specific for guanine
binding rather than adenine and Glutamine-61 is the crucial residue that activates a catalytic water
molecule for hydrolysis of GTP to GDP. G2 and G3 are often involved in effector interactions
and play an important role in the interaction with guanine nucleotide exchange factor (GEFs) and
stimulating GTP hydrolysis by interacting with GTPase activating proteins (GAPs). The two
switch motifs, G2 and G3 are the major parts of the protein that move upon activation by GTP.
This change in conformation of the two switch motifs is what mediates the basic functionality as
a molecular switch protein by affecting the interaction with other proteins, i.e., effectors; hence
they are named switch regions. G4 is the N/TNKxD motif, where aspartate contacts nitrogen
atoms of the base and asparagine contacts the oxygen of the purine, thus providing a specific
interaction to guanine. G5 has a weakly conserved SAK sequence where the alanine-146 is
specific for guanine rather than the adenine amino group (Vetter, 2014; Vetter and Wittinghofer,
2001).
The C-terminal hypervariable domain (amino acids 166-188/189) is highly diversified
across all the RAS isoforms. The HVR consists of very well characterized anchor sequences,
which are responsible for trafficking RAS molecules to membranes. The terminally located
CAAX motif (C=Cystiene, A= aliphatic amino acid, X=any amino acid) forms the minimal RASanchor signal, which is the site for the attachment of farnesyl moiety to the cysteine residue of
CAAX by a cytosolic enzyme, farnesyl transferase. Farnesylation targets RAS proteins to the
endoplasmic reticulum (ER), where the terminal 3 amino acid residues (AAX) are removed by a
protease residing in the ER, called RAS converting enzyme 1 (RCE1) (Konstantinopoulos et al.,
2007). Subsequently, the carboxyl group of the terminal cysteine is methyl esterified by
isoprenylcysteine carboxymethyl transferase (ICMT). In addition to this, the HVR of all RAS
isoforms consist of an additional second signal immediately upstream of this first signal,
consisting of single to multiple cysteine residues for palmitoylation, except in the case of KRAS-
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4B, which consists of a polybasic domain of six continuous lysine residues (K175-K180) instead
of cysteine residues, which allows it to bypass the golgi and reach the plasma membrane directly
(Ahearn et al., 2012; Konstantinopoulos et al., 2007). These post-translational modifications
convert an otherwise globular, hydrophilic protein to one that associates with the cytoplasmic
leaflet of cellular membranes, which enables the activation of RAS and subsequent downstream
signaling.
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Figure 1.6. Conserved structure and domains of mammalian RAS proteins: All RAS
proteins contain two distinct domains: (1) G-domain and (2) Hypervariable domain/region
(HVR). The G-domain (amino acids 1-165) is comprised of five conserved guanine nucleotide
consensus sequence elements that are responsible for Phosphate/Magnesium or guanine
nucleotide binding. The G-domain is highly homologues across all the RAS isoforms (HRAS,
NRAS, KRAS-4A and KRAS-4B). The first 85 amino acids of the G-domain are 100% identical
in all four isoforms. The C-terminal HVR (amino acids 166-188/189) is highly diverse and is
responsible for specifying the membrane localization of RAS isoforms via posttranslational
modification, which include farnesylation of a unique cysteine residue at the C-terminal CAAX
box (red), and palmitoylation of cysteine (blue) upstream of the Cysteine at the CAAX box. Blue
boxes indicate the guanine nucleotide-binding region. The black (switch I) and grey box (switch
II) refers to regions which dynamically undergo conformational change depending on GDP or
GTP binding to Ras proteins, which in turn contribute to preferential effector binding to the GTPbound state and the core effector binding region (pink box). The stretch of 6 successive lysine
residues in KRAS-4B is responsible for direct membrane targeting without processing in the
golgi.
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1.2.3. Functional regulation of RAS proteins
RAS proteins are guanine nucleotide-binding proteins (G proteins) of a RAS superfamily, which
transduce extracellular signals into intracellular changes through second-messenger cascades.
Despite the diversity in structure of all the members of RAS gene family, they all possess the
ability to bind GDP/GTP and have intrinsic GTPase activity that enables RAS proteins to switch
between inactive and active states. The molecular switch mechanism of GDP/GTP exchange in
RAS family proteins is tightly regulated within the cells by a complex interplay of regulator
proteins like GTPase activating proteins (GAPs) and guanine nucleotide exchange factors
(GEFs). Besides the switch mechanism of activation of RAS by regulator molecules, biological
activity of RAS proteins are highly regulated by post-translational modification at its C-terminus
and trafficking to membranes which involves a number of highly regulated steps and modifying
enzymes.
Because of the extremely high affinity of G proteins for GDP/GTP (within nano to
picomolar range), the intrinsic dissociation rate of nucleotides is extremely slow within the cells.
GEFs (CDC25 in Saccharomyces cerivisiae, and SOS, RAS-GRF and RAS-GRP in mammals)
however, potentiate the rapid signal transduction by catalyzing the rapid exchange of GDP for
GTP by modifying the nucleotide-binding site in such a way that the overall affinity of RAS to
guanine nucleotide is decreased. In general, GEFs act as positive regulators of RAS activity.
GEFs have no special affinity for binding to either GDP or GTP, but because of approximately
10-fold higher concentration of GTP over GDP within the cells, the binding of GTP is more
favored. Mechanistically, GEF binding induces conformational changes in the switch regions and
P-loop without affecting remainder of the domain structure of RAS proteins. Interestingly,
biochemical studies have highlighted that the affinities of both GEFs for nucleotide-bound G
proteins and of the guanine nucleotide for GEF-bound G proteins are very low, thus the
interaction of GEFs weakens the affinity for the nucleotide and vice versa. As a result, in the
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course of the exchange reaction the GEF displaces bound nucleotide, and subsequently a new
nucleotide displaces GEFs (Fig 1.7).
Like any other G proteins, all the members of RAS family possess intrinsic GTPase
activity. However, this intrinsic GTP hydrolyzing activity of RAS is very slow and inefficient,
which makes it unsuitable for rapid inactivation of signal transduction in case of absence of
external growth factor stimuli. Thus, interaction of RAS with GTPase activating protein (GAP)
enhances the GTP hydrolyzing activity by several magnitudes resulting in net negative regulation
of RAS activity (Fig 1.7). The mechanistic insight into the activation of GTPase activity of the
RAS protein was first obtained in 1997 from the crystal structure of the RAS-RAS.GAP complex.
It was proposed that RAS.GAP stabilizes glutamine at the 61st position of RAS, which
coordinates with water during nucleophilic attack. In addition to this, an arginine (called
“arginine finger”) is positioned into the phosphate-binding site and hence stabilizes the transition
state. This hypothesis is currently supported by various biochemical and mutational studies. For
example, oncogenic mutation at glutamine 61, which occurs frequently in many human cancer
types abolishes GAP induced GTP hydrolysis. Similarly, other common mutations in RAS at the
12th and 13th amino acid positions eliminates GAP-induced hydrolysis by blocking the appropriate
orientation of both arginine finger and glutamine 61 by steric hindrance (Bos et al., 2007; Vetter
and Wittinghofer, 2001).
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Figure 1.7. Activation and inactivation of RAS proteins (GDP-GTP Cycle): The activation
state of Ras is controlled by its cycling between the GTP or GDP bound state. RAS proteins are
inactive when bound to GDP, which is activated by a guanine nucleotide exchange factor (GEF).
GEF catalyzes the rapid release of bound GDP that in turn allows binding of GTP, which is
present in excess concentrations as compared to GDP within the cell. GTP binding causes a
dramatic conformational change in RAS, which allows it to bind with its effector partners
resulting in downstream, signal transduction. The active (GTP-bound) form of RAS is again
turned-off to an inactive state by rapid hydrolysis of bound GTP by guanine nucleotide activating
protein (GAP).
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1.2.4. Canonical RAS signaling pathway
RAS proto-oncogenes are membrane bound signal transducers that help in relaying the messages
from outside of the cell to inside of the cell to mediate different cellular responses like
proliferation, growth and survival. Binding of growth factors to cell-surface cognate receptors
results in the activation of receptors causing in dimerization (in most cases) and autophosphorylation. This activation of receptors results in the recruitment of downstream effectors
ensuing in the formation of receptor complexes consisting of adaptor proteins like SHC (SH2containing protein), GRB2 (growth-factor-receptor bound protein 2) and GAB (GRB2-associated
binding) proteins. These proteins recruit GEFs (SOS), which increases the level of GTP bound
RAS (RAS-GTP) levels by catalyzing nucleotide exchange on RAS (Fig 1.8). Numerous RASGTP effector pathways have been identified, however the extracellular signal-regulated kinase
(ERK) pathway and the phosphatidylinositol 3-kinase (PI3K)/AKT pathways are considered the
most important effector pathways regulated by RAS signaling. The BRAF–mitogen-activated and
extracellular-signal regulated kinase kinase (MEK)–extracellular signal-regulated kinase (ERK)
cascade determines proliferation, and is often deregulated in human cancers. RAS can directly
bind to PI3K via its PI3K binding domain (PBD) and activate the phosphatidylinositol 3-kinase
(PI3K)–protein kinase-B (PKB/AKT). Stimulation of this effector pathway determines cellular
survival. RAS also binds and stimulates the enzyme phospholipase Cε (PLCε), the hydrolytic
products of which regulate calcium signaling and the protein kinase C (PKC) family. Once the
external growth factor signaling cues subside, the GAPs (p120GAP and Neurofibromin-1 [NF1])
bind to RAS–GTP and accelerate the conversion of RAS–GTP to RAS–GDP (guanosine
diphosphate), which terminates the signaling within minutes to hours.
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Figure 1.8. The canonical RAS signaling pathway: Binding of growth factors to its cognate
cell surface tyrosine kinase receptors (RTK) result in activated receptor complexes, which recruit
various adaptor proteins like GRB2 and GEF (SOS), which in turn, converts inactive RAS-GDP
to activated RAS-GTP. This activates various downstream signaling events by recruiting varieties
of effector proteins. This results in physiological effects like proliferation, survival and migration
of cells.

36

Figure 1.8.
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1.2.5. RAS function in tissue homeostasis and normal development
RAS proteins are essential transducer proteins for the normal function of eukaryotic cells
(mammalian and non-mammalians) at physiological conditions (Deshpande and Kung, 1987;
Medema et al., 1991; Mulcahy et al., 1985; Stacey et al., 1991a; Stacey et al., 1991b). Numerous
seminal studies in yeast and mouse fibroblast cells using neutralizing antibodies and synthetic
dominant negative RAS mutants have helped to understand the critical role of RAS as a regulator
of different growth factors within the cell. Despite the significant understanding of the role of
different RAS isoforms within the cellular context, the unique and redundant roles of each
isoforms in the context of organs and in the maintenance of physiological functions were limited
until the development of gene knock-out mice for each individual RAS isoforms.
A number of conventional gene knockout (gene disruption approach) mice have been
generated (Table 1.1) in an attempt to better understand the physiological functions of individual
RAS isoforms in vivo. The targeted gene knockout approach was first use to disrupt the Nras
gene in mice. Mice deficient for Nras are viable and are indistinguishable from their wild-type
counterpart, suggesting it is dispensable for normal development, growth and fertility of mice
(Umanoff et al., 1995). However, Nras deficient mice have a low number of CD8 positive
thymocytes, defective T-cell function and antiviral immune response when challenged with
Influenza A virus (Perez de Castro et al., 2003). Similar to Nras knockout mice, Hras null mice
are viable and do not have any discernible phenotype (Esteban et al., 2001; Ise et al., 2000). A
compound knockout study has shown that a combination of both Hras and Nras genes are
dispensable for the normal development, growth, fertility and neuronal development of mice
(Esteban et al., 2001). Despite the dispensable role of HRAS in normal development, HRAS is
critical in carcinogen induced skin carcinogenesis. However, activation of KRAS can compensate
for the Hras activation in Hras deficient mice during the early phase of skin tumor development,
suggesting a partial redundant role of HRAS and KRAS (Ise et al., 2000).
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In contrast, to Nras and Hras, the Kras gene is indispensable for mouse embryogenesis
and development. Kras deficient mice die during mid-gestation at embryonic day 10.5 to 12.5 due
to defects in liver, hematopoiesis, myocardial cell proliferation and neuronal survival (Johnson et
al., 1997; Koera et al., 1997), suggesting that KRAS is an essential gene with a unique
physiological function that cannot be compensated for by both Hras and Nras during embryonic
development. More specifically, the Kras-4B but not the Kras-4A splice variant is indispensable
for mouse development (Plowman et al., 2003). However, a more cautious analysis of the results
from double or triple ras mutant (Nras, Hras and Kras) mice indicated a partial overlapping
function of each of the isoforms. For example, Nras-/-/Kras+/- mice are embryonically lethal,
while Nras-/- and Kras+/- mice are both viable suggesting a partial functional overlap between
NRAS and KRAS (Goodell et al., 1997; Johnson et al., 1997; Nakamura et al., 2008). On the
other hand, overexpression of exogenous HRAS in Kras deficient or ras triple (Nras, Hras and
Kras) mutant mice eliminated the overt abnormalities in the development of ras mutant mice,
supporting the idea that RAS proteins are functionally overlapping during mouse development
(Nakamura et al., 2008). Similarly, replacement of the Kras with Hras, using Kras knock-in mice,
where the expression of Hras was directed from the Kras gene loci, resulted in the normal
embryonic development but with dilated cardiomyopathy in adult mice. This finding pointed
towards the idea that Hras can essentially replace the Kras for its function during embryogenesis,
and indicates that KRAS has a unique role in cardiovascular homeostasis (Potenza et al., 2005).
Thus, the inconsistency in conclusions from recent ras gene deletion studies with earlier studies
that show KRAS possesses unique functions that are not shared by Nras and Hras may be based
on the fact that KRAS is expressed in a specific cell type in differentially regulated manner
during a critical stage of development, or may be due to the temporal difference in the expression
pattern of individual RAS isoforms during embryonic development. So the difference in
phenotypes of individual ras knockout mice might be due to differential regulation of each gene
rather than the properties of the proteins themselves.
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Collectively, results from the conventional ras gene knockout studies suggest that Kras is
the most essential ras gene. It plays a unique role in embryogenesis and in the development of
various organs in mice. It also has partial functional overlap with Nras and Hras. However, since
conventional Kras knockout mice die during embryogenesis, the post-natal role of KRAS in
homeostasis of various organs remains elusive. Generation of mouse strains that carry conditional
Kras alleles alone or in various combinations of Hras and Nras backgrounds should provide
valuable information to delineate the role of individual ras genes in specific tissues and/or
developmental stages by using tissue specific, constitutive or conditional Cre lines.
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Table 1.1. Currently available mouse models to study RAS function in vivo
Gene

Mutation Description

Phenotype Description

References

Kras

Targeted deletion

Embryonic lethal (E12-E14).

(Koera et al., 1997)

(Conventional KO)

Fetal liver defect.

(Johnson et al., 1997)

(Kras

tm1Tyj

)

Abnormal hematopoiesis.
Anemia.
Hras
(Hras

tm1Esn

)

Targeted deletion

No Phenotype.

(Conventional KO)

Decreased tumor incidence on (Esteban et al., 2001)

(Hrastm1Mok)

carcinogen treatment.

Nras
(Nras

tm1Rak

(Nras

tm1Mok

)

Targeted deletion

Viable.

(Umanoff et al., 1995)

(Conventional KO)

Defective immune response.

(Perez de Castro et al., 2003)

Defective T-cell function.

(Nakamura et al., 2008)

Dilated cardiomyopathy.

(Potenza et al., 2005)

)

Hras
(Kras

(Ise et al., 2000)

Targeted Insertion
tm1(Hras)Rdl

)

(insertion of Hras gene into Enlarged myocardial fiber.
endogenous Kras locus.)

Cardiac fibrosis.

41

1.2.6. RAS signaling in developmental disorders
RAS was first identified as a transforming agent responsible for the formation of sarcoma in rats,
and later as the first human oncogene (HRAS) responsible for the malignant transformation of
human bladder cells by acquiring a gain-of-function point mutation. Despite the well-known and
widely studied role of RAS gene mutations in a variety of human cancers, germline mutations in
RAS genes have also been associated with a small number of human developmental disorders.
Noonan Syndrome (NS), a relatively common autosomal dominant congenital disorder is
characterized by congenital heart defect, short stature, learning disability, impaired blood clotting
and characteristic facial features including flat nose bridge and webbed neck. The features of NS
overlaps with other developmental disorders like Costello and Cardiofaciocutaneous (CFC)
syndromes (discussed later). The etiology behind NS is due to the mutations in genes of the RAS
pathway, like PTPN11, SOS1, RAF1, KRAS, NRAS and BRAF. Although the frequency of
KRAS mutations in Noonan Syndrome is very low (approximately 2%), the mutations in this
gene are usually associated with a more severe or atypical form of this disorder. The KRAS
mutants identified in the case of Noonan Syndrome are unique to this disease and are not found in
any case of cancer. The most common form of KRAS mutations associated with Noonan
Syndrome are- V14I and T58I. The intrinsic GTPase of NS associated KRAS mutant are lower
than wild-type KRAS, but less impaired than oncogenic G12D KRAS mutants. Thus these NS
associated KRAS mutants are less activated than oncogenic KRAS. Other mutants of KRAS-4B
isoforms are also identified in some patients with NS, including V12G, D133V and F156I
(Allanson, 2007; Schubbert et al., 2007a; Schubbert et al., 2007b; Schubbert et al., 2006). Besides
mutations in KRAS, NRAS germline mutations are also identified in extremely rare cases of NS.
Substitution mutations of NRAS, I24N, P34L and P34R have been identified in cases of NS
(Denayer et al., 2012).
Costello Syndrome (CS) is another rare autosomal dominant developmental disorder
affecting about 200 to 300 people worldwide. Intellectual disability, retarded development,
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unusually flexible joints, loose folds of skin and distinctive facial features, including enlarged
mouth, characterize it. Heart defects are also common in this disease. As mentioned earlier, signs
and symptoms of CS significantly overlap with NS (Quezada and Gripp, 2007). Patients with CS
are predisposed to specific type of cancers like rhabdomyosarcoma, gangliosarcoma,
ganglioneuroblastoma and gastric cancer. So far, only mutant HRAS is known to cause this
disease. At least 15 different mutations in the HRAS gene have been identified in people affected
with CS (Estep et al., 2006; Rauen, 2007). The most common HRAS mutation, accounting for
more than 80% of all CS is the Glycine to Serine mutation at 12th codon (G12S), which is very
uncommon in cancers. Almost all CS patients carry amino-acid substitution in HRAS at codons
12 and 13 similar to somatic mutations in tumors. Germline mutations encoding K117R and
A146T HRAS substitutions have also been reported in CS (Aoki et al., 2005; Estep et al., 2006;
Schubbert et al., 2007b). For more information on this subject see the Genetics Home Reference
page maintained by National Institute of Health (http://ghr.nlm.nih.gov/condition/costellosyndrome).
Cardiofaciocutaneous (CFC) syndrome is another type of rare autosomal dominant
genetic condition that specially affects heart, facial features and skin, hence named
Cardiofaciocutaneous Syndrome. Children with this disease are identified with relatively large
head, down-slanting eyes, sparse eyebrows, scaly skin, curly hair and small stature with a heart
defect in most cases (http://www.cfcsyndrome.org/). Similar to Costello Syndrome, CFC also
shares significant similarity in features. CFC is caused by mutations in several genes of the RASMAPK pathway. Gene mutation in BRAF are the most common, accounting for more than 75%
of all CFC cases (Gripp et al., 2007; Rauen, 2006; Schubbert et al., 2007a; Schubbert et al.,
2007b). MAP2K1, MAP2K2 and KRAS are the other genes except BRAF of RAS-MAPK pathway
that are mutated in CFC. Germline mutations in the KRAS gene, however, are uncommon in CFC,
accounting for less than 2-3% of all cases (Niihori et al., 2006; Rauen, 1993). For more
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information on this subject visit the Genetics Home Reference page maintained by National
Institute of Health (http://ghr.nlm.nih.gov/gene/KRAS).
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1.2.7. RAS and cancer
RAS genes were originally identified as the cell-transforming elements of Harvey and Kirsten
strains of rat sarcoma viruses (Malumbres and Barbacid, 2003). Later, mutationally activated
allele of cellular HRAS genes was identified as the first human oncogene responsible for cellular
transformation in human EJ/T24 bladder carcinoma cells (Pulciani et al., 1982; Reddy et al.,
1982; Santos et al., 1982; Shih and Weinberg, 1982; Tabin et al., 1982; Taparowsky et al., 1982).
Subsequently, other isoforms of human RAS genes (KRAS and NRAS) were identified as dominant
oncogenes in variety of human cancer types (Almoguera et al., 1988; Der et al., 1982; Hall et al.,
1983; Santos et al., 1984; Shimizu et al., 1983; Smit et al., 1988). According to the National
Cancer Institute (NCI), RAS genes are the most frequently mutated oncogenes in human cancers,
accounting for more than 30% of all the human cancer cases. Despite the ubiquitous presence and
a powerful transforming ability of each members of RAS proteins in model systems, mutations in
RAS genes occur at varying frequency, with KRAS mutation (85%) being the most frequent,
followed by NRAS (15%) and HRAS the least frequent (<1%) (Downward, 2003; Stephen et al.,
2014). Activating mutations in Ras occur mainly in 3 mutational hotspots, at codons 12,13 and
61, although other rare mutations are also observed in human cancers. Point mutations in RAS at
these hotspots are associated with its activation by abolishing GAP-induced GTPase activity as a
direct consequence of a conformational change in the RAS structure. This results in a constitutive
activation of RAS proteins by preventing GTP hydrolysis ultimately locking it in a GTP bound
state.
Based on the Catalogue of Somatic Mutations in Cancer (COSMIC) database, mutations
in the KRAS gene are associated with the highest percentage of all human cancers (21.6%)
(Baines et al., 2011; Forbes et al., 2011). Characteristically, activation mutations in the KRAS
gene occurs predominantly at codon 12 (>80%) whereas very few at codon 13. Mutations in the
KRAS gene have been detected in numerous human tumor types, predominantly in pancreatic
adenocarcinoma, colon carcinoma, biliary tract tumor, and lung adenocarcinoma (Table 1.2).
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KRAS mutation is also present in many other cancers like cervical cancer, endometrial cancer,
ovarian cancer, liver cancer and myeloid leukemia, but at a very low frequency (Jancik et al.,
2010; Prior et al., 2012). On the other hand, NRAS mutations are most frequently observed in
melanoma, hematopoietic neoplasms, liver carcinoma and thyroid carcinoma, with a relatively
lower frequency in tumors of the ovary, testis and adrenal glands. Unlike KRAS, most activation
mutations in NRAS primarily occur at codon 61 (approximately 60%) (Prior et al., 2012). HRAS
mutations are most common in tumors of the salivary gland, stomach, skin, cervix, prostate, testis
and thyroid, with less frequent occurrence in tumors of thymus, bone and esophagus. Unlike,
KRAS and NRAS, HRAS does not show preferential codon specificity for mutations in the
mutation hotspots. Most HRAS mutations occur at codon 12 and 61 at an almost equal rate
(Karnoub and Weinberg, 2008; Prior et al., 2012; Schubbert et al., 2007b).

1.2.8. KRAS and pancreatic cancer
Perucho and colleagues were the first to demonstrate the association of pancreatic cancer with
activation mutation in KRAS gene, using very a elegant approach of gene amplification by
polymerase chain reaction (PCR) and mutation detection by RNAase A mismatch cleavage. They
demonstrated that 21 out of 22 (95%) carcinomas of the exocrine pancreas contained a KRAS
mutation at codon 12 exclusively, providing very strong evidence for the possible role of KRAS
mutation in the pathogenesis of human pancreatic cancer (Almoguera et al., 1988). Subsequently,
two independent research groups reported similar findings (codon 12 mutation in KRAS in 75%
and 95% pancreatic tumor samples, respectively), further highlighting the role of the mutational
activation of KRAS, more specifically a mutation at codon 12, in human pancreatic
adenocarcinoma (Grunewald et al., 1989; Smit et al., 1988). Many others have since
demonstrated the association of KRAS mutation in human pancreatic cancer. Kloppel and
colleagues, later found that the mutation at codon 12 of KRAS was present in early pre-neoplastic
ductal lesions along with invasive ducal adenocarcinoma, further strengthening the claim that
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activating mutations in the KRAS gene are important for the initiation of pancreatic ductal
adenocarcinoma (Lemoine et al., 1992). According to the COSMIC database, over 60% of the
patients with invasive pancreatic cancer harbor activating mutations in KRAS (Table 1.2).
Despite the strong correlation of activated KRAS mutations and invasive human
pancreatic adenocarcinomas, there was no direct evidence in support of the long-standing
hypothesis that these mutations were responsible for tumor initiation. In fact, doubts and
questions were being raised regarding the significance of KRAS mutations in pancreatic
carcinogenesis, as KRAS mutations were found even in the normal-appearing ductal epithelium
of the inflamed as well as non-inflamed non-neoplastic pancreas (Luttges et al., 2000; Luttges et
al., 1999). Even though vehement efforts were made to validate the pancreatic cancer-initiating
efficacy of oncogenic KRAS in transgenic mice by targeting the expression of mutant KRAS
under acinar and ductal promoters, neither model developed PDAC and failed to recapitulate
human disease progression; possibly because of the hyper-physiological level of KRAS or due to
its activation in inappropriate cells (Brembeck et al., 2003; Grippo et al., 2003). This had further
raised doubt over the contribution of oncogenic KRAS in pancreatic cancer pathogenesis.
However, it was only in 2003, when the role of oncogenic KRAS in pancreatic cancer initiation
was validated experimentally. Using Cre-recombinase inducible conditional knock-in mice for
the expression of the mutant allele of Kras (KRASG12D) exclusively in progenitor cells of the
pancreas, two independent research groups successfully demonstrated that the oncogenic form of
KRAS could induce an entire spectrum of genuine pancreatic ductal adenocarcinoma from preinvasive neoplasia to invasive and metastatic disease in mice (Aguirre et al., 2003; Hingorani et
al., 2003). Since then, numbers of other genes that work in collaboration with Kras in pancreatic
cancer pathogenesis have been characterized using multiple other genetically engineered mouse
models (Table 1.3).
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Table 1.2. Frequencies of RAS mutations in human cancers (in percentage)
Tumor Type

HRAS

KRAS

NRAS

Biliary tract

0

22

3

Breast

0

1

0

Cervix

4

6

<1

Endometrium

0

14

0

0

5

9

0

<1

0

Large Intestine

0

36

4

Liver

0

1

<1

Lung

<1

16

<1

Ovary

0

12

<1

Pancreas

0

65

<1

Prostate

2

4

<1

Skin

11

2

16

Small Intestine

0

23

1

Stomach

<1

6

1

Testis

3

4

2

Thyroid

4

2

7

Urinary Tract

9

4

4

Hematopoietic
Lymphoid
Kidney

and

All the mutation data for all tumor types for the specified organs were obtained from
Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC
v74) database (Last accessed on 02/12/2016).
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Table 1.3. Currently available genetically engineered mouse models of PDAC
Genotype

Key Pathological Features

References

Pdx1-Cre; LSL-KrasG12D

PanINs and PDAC with

(Hingorani et al., 2003)

occasional metastasis.
LSL-KrasG12D;

Pdx1-Cre;
Cdkn2alox/lox

G12D

; LSL-

R172H/+

Cdkn2a-/LSL-KrasG12D;

lox/lox

lox/lox

LSL-Kras
; Cdkn2a

Pdx1-Cre;

G12D

;

-/-

Ptf1a-Cre;

LSL-KrasG12D;
LSL-KrasG12D;

PanINs and PDAC with very

(Bardeesy et al., 2006a)

IPMNs, PanINs and PDAC

(Bardeesy et al., 2006b)

PanINs and PDAC with

(Ijichi et al., 2006)

metastasis.
LSL-Kras

G12D

;

LSL-KrasG12D;

Notch2lox/lox
Pdx1-Cre;

High-grade PanINs.

(Hanlon et al., 2010)

Pdx1-Cre;

LSL-KrasG12D;

with

delayed

(Mazur et al., 2010)

PanIN and PDAC without

(Morton et al., 2010)

detectable metastasis.
LSL-Kras

G12D

;

lox/lox

Ptf1a-Cre;

PDAC

progression phenotype.

lox/lox

PTEN

(Bardeesy et al., 2006a)

lox/lox

Ptf1a-Cre;

Lkb1

PanINs and PDAC without

with metastasis.

lox/lox

Pdx1-Cre;
Notch1

(Bardeesy et al., 2006a)

high metastasis.

Smad4lox/lox

TGFβIIR

PanINs and PDAC with very

metastasis.

Pdx1-Cre;
Trp53

(Hingorani et al., 2005)

high metastasis.

Pdx1-Cre;
Trp53

PanINs and PDAC with very
high metastasis.

LSL-KrasG12D;

Pdx1-Cre;

(Aguirre et al., 2003)

with occasional metastasis.

Pdx1-Cre; LSL-Kras
Trp53

PanINs and invasive PDAC

PanINs and PDAC with

(Hill et al., 2010)

occasional metastasis.
LSL-KrasG12D;

PDAC with metastasis.

(Izeradjene et al., 2007)

PDAC only on pancreatitis

(Carriere et al., 2007)

Smad4lox/lox
Nestin-Cre; LSL-KrasG12D

induction. No metastasis.
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LSL-KrasG12D;

Ptf1a-Cre;
Yap1lox/lox

LSL-KrasG12D;

lox/lox

of

(Zhang et al., 2014)

Delayed formation of PanIN

(Corcoran et al., 2011)

and PDAC.

Elastase-tTA; TetO-Cre; LSLKras

abrogation

PanIN and PDAC formation.

Pdx1-Cre;
Stat3

Complete

G12V

PDAC with metastasis in

(Guerra and Barbacid, 2007)

context of pancreatitis only.

Elastase-CreERT2;

LSL-

KrasG12D

Low to high-grade PanINs
without

PDAC

(Habbe et al., 2008)

without

pancreatitis.
Mist1-CreERT2; LSL-Kras

G12D

Low to high-grade PanINs
without

PDAC

(Habbe et al., 2008)

without

pancreatitis.
Ptf1a-Cre;
TetO-Kras
Ptf1a-Cre;

Rosa26-LSL-rtTA;
G12D

; Trp53

+/-

Rosa26-LSL-rtTA;

TetO-LSL-KrasG12D; Trp53lox/lox

Reversible PDAC without

(Collins et al., 2012a)

metastasis.
Reversible PDAC without
metastasis.
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(Ying et al., 2012)

1.3. Concluding remarks and dissertation hypothesis
Pancreatic cancer is one of the most lethal types of cancers (<6% 5-year survival rate) with an
annual incidence rate of approximately 44,500 cases (2015 Cancer Facts & Figures of the
American Cancer Society). Effective early detection and screening modalities are currently not
available, and tumors are typically diagnosed following metastasis. Tumors arise in the pancreas
with features of three major cell types (i.e., ductal, acinar and endocrine cells), but the vast
majority (>90%) are ductal adenocarcinomas (DiMagno et al., 1999). Pancreatic ductal
adenocarcinoma (PDAC) has several types of precursor lesions and among those, pancreatic
intraepithelial neoplasia (PanIN) is the most common (Hruban et al., 2000; Hruban et al., 2007;
Hruban et al., 2004). Genomic and molecular studies have identified a number of oncogenes and
tumor suppressor genes, and suggested that they play a role in the initiation and progression of
pancreatic cancer. During the progression of PanINs into PDACs, somatic mutations accumulate
within critical tumor susceptibility loci, including KRAS, CDKN2A, TRP53, and SMAD4. Gainof-function mutations in KRAS and the upregulation of this oncogene occur frequently in human
PDACs. Since these genetic changes have been identified in precursor lesions associated with
PDACs, it is evident that KRAS is a very early event in pancreatic cancer initiation (Hruban et
al., 2000). Consistent with the central role of KRAS in human neoplasia, mice engineered with a
pancreas-specific expression of activated KRAS (KRASG12D) develop classical PanIN lesions that
progress into PDAC in the appropriate tumor suppressor background (e.g. deficiency in Cdkn2a)
(Aguirre et al., 2003; Hingorani et al., 2003).
Despite a wealth of knowledge about the importance of KRAS and other oncogenes
during the onset of pancreatic cancer, the importance of this cancer-initiating mutation during the
late stages of disease progression remained. Studies using RNA interference or a dominantnegative mutant of KRAS suggest that KRAS plays a role in pancreatic cancer cell growth and
survival in vitro (Fleming et al., 2005). However, there is insufficient genetic evidence to suggest
that ablation of oncogenic Kras has an effect on maintenance of the primary tumor and metastatic
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dissemination in vivo. Our study aims to fully address the importance of oncogenic KRAS at the
most advanced stages of pancreatic tumor progression in vivo using a conditional/reversible
tumor model system. We hypothesize that oncogenic KRAS is required for both the initiation and
maintenance of pancreatic ductal adenocarcinoma; hence genetic ablation of KRAS in invasive
adenocarcinoma will result in tumor regression.
Using a novel reversible tumor model system for conditional expression of the c-MYC
oncogene, our lab has previously demonstrated that upregulation of c-MYC is sufficient to induce
pancreatic ductal adenocarcinoma in mice (Lin et al., 2013). Moreover, expression of c-MYC is
required for the survival of cancer cells at primary and metastatic sites, providing important
evidence suggesting that pancreatic cancer cells are dependent upon persistent expression of the
tumor driving oncogene for their survival. However, despite the complete macroscopic regression
of primary and metastatic pancreatic cancer upon downregulation of c-MYC, a few cancer cells
were able to survive oncogene ablation, and were able to swiftly re-induce tumors following reexpression of c-MYC. This finding suggests that, despite the dependence of a majority pancreatic
cancer cells upon the tumor-driving oncogene for their survival, a few cancer cells have the
ability to survive the oncogene ablation and hence may be responsible for tumor relapse. Based
on our previous findings from our c-MYC-induced pancreatic cancer model, we hypothesize that
despite the dependence of pancreatic cancer cells upon oncogenic KRAS, a few cancer cells will
be able to survive Kras-ablation and will be responsible for tumor relapse upon Kras reexpression. The main purpose of this work is to understand if downregulation of oncogenic
KRAS in invasive pancreatic cancer results in the complete elimination of tumor cells or
alternatively results in residual disease. Our goal is also to identify, isolate and characterize the
residual cancer cells in residual disease. Collectively, the outcome of our study will address
whether or not the targeted therapies directed against KRAS will be able to completely cure
advanced stages of pancreatic cancer. At the same time, it will help to develop additional
therapeutic strategies to eliminate residual cancer cells to prolong survival of pancreatic cancer

52

patients by preventing disease relapse.
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Chapter 2: Materials and Methods
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2.1. Mouse models:
All the mice used in this study were bred in FVB/C57B6 mix backgrounds in a pathogen-free
environment. The following mouse models were used in this study: Pdx1-Cre (Hingorani et al.,
2003), CAG-Lox-βgeo-Lox-tTA (CAG-tTA) (Zhang et al., 2010), TetO-KRASG12D (Fisher et al.,
2001), TetO-Myc (Felsher and Bishop, 1999), CAG-Lox-STOP-Lox-GFP (CAG-GFP)
(Kawamoto et al., 2000), TetO-Luciferase (TetO-Luc), Cdkn2a knockout mice (Serrano et al.,
1996). Pdx1-Cre and Cdkn2a mutant mice were obtained from the NCI repository. All the
animals used in this study were treated humanely in accordance with guidelines of University of
Nebraska Medical Center (UNMC) Institutional Animal Care and Use Committee (IACUC).

2.2. Mouse genotype analysis:
Approximately 0.5cm piece of tail 3 week old mice were snipped and digested overnight at 56oC
in 500uL of tail digestion buffer (1% SDS, 50uM Tris-HCL [pH 8.0], 100 mM NaCl, 50mM
EDTA with freshly added 400ug/ml proteinase K) for the extraction of genomic DNA. Overnight
digested samples were centrifuged at 13,000 rpm for 20 minutes and supernatants were
subsequently transferred to clean tubes without disturbing the pellets. Genomic DNA was isolated
using the AutoGen NA-2000 DNA extraction robot (Autogen, Holliston, MA), which utilizes a
standard phenol-chloroform DNA extraction method. Purified genomic DNA was used for
genotyping PCR. Each PCR reaction mixture consisted of: 32.3uL of ddH2O, 10 µL 5x PCR
reaction buffer (Promega, Fitchburg, WI), 3 µL MgCl2 (25mM) (Promega, Fitchburg, WI), 1 µL
of dNTPs mix (10 mM) (Invitrogen, Carlsbad, CA), 0.5 µL of both forward and reverse primers
(100 pM), 0.5 µL of 5U/µL GoTaq DNA polymerase (Promega, Fitchburg, WI) and 1 µL of
purified genomic DNA extracted from tail (total reaction volume = 50 µL). All the PCR primers
and PCR cycling conditions used during genotyping are listed in Table 2.1. After PCR
amplifications, the amplicons were run on a 2% agarose gel containing 3% v/v Ethidium Bromide
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(prepared in 1X Tris-EDTA buffer, pH 7.5), and visualized using BioDoc-It Imaging system from
UVP (Upland, CA).

2.3. Doxycycline treatment and in vivo luminescence imaging:
All the mice were treated with 2 mg/ml doxycycline (Dox; Sigma, St. Louis, MO) mixed with 20
g/l sucrose (Fisher Scientific) in their drinking water during the entire breeding duration until the
newly born litters were 10 days of age to prevent the deleterious effect of oncogenic KRAS
during the early embryonic developmental stage. For the down-regulation of oncogenic KRAS in
fully developed tumors, tumor-bearing mice were treated with Dox for the indicated time points.
The expression and activity of the luciferase reporter gene was monitored using an in vivo
bioluminescence imaging machine (IVIS200, Caliper Life Sciences, Alameda, CA) after
peritoneal injection of luciferin (150 µg/kg body weight D-Luciferin potassium salt; Xenogen
#XR-1001) ten minutes prior to the imaging procedure.

2.4. Generation of cell lines and maintenance in cultures:
Freshly isolated pancreatic tissues were digested in a dissociation medium containing
Collagenase IV (200U/ml, Sigma #C2674-1G), Dispase-II (0.6 U/ml, Roche Diagnostics
#165859) and DNase-I (100 U/ml, Sigma #D5025-150KU) in DMEM (FBS-free) medium (Gibco
#11965-084) for 1.5-2 hours at 370C with frequent shaking/vortexing at every 20 min interval.
Dissociated single cells were passed through a 45 µm filter and plated in DMEM medium
supplemented with 10% FBS (Atlas Biologicals, F-0500-A), L-Glutamine (2 mmol/l, Gibco
#25030-081, non-essential amino acids (Gibco #11140-050), Penicillin (10 U/ml, Gibco #15140122), Streptomycin (10 µg/ml, Gibco #15140-122) and Gentamicin (50 µg/ml, Gibco #15750078). Single clones were carefully picked and characterized, and maintained at low passage (15
passages) in this media condition. Media was changed every 2-3 days unless otherwise
mentioned. For the down-regulation of oncogenic KRAS and c-MYC in vitro, murine pancreatic
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cancer cells were treated with Doxycycline at 2 µg/ml concentration and were changed every 2-3
days unless otherwise indicated. Human pancreatic cancer cell lines AsPC-1 and MIA PaCa-2
were maintained in RPMI-1640 medium (Gibco #11875-093) supplemented with 10% FBS,
Penicillin (10U/ml, Gibco #15140-122), Streptomycin (10 µg/ml, Gibco #15140-122) and
Gentamicin (50 µg/ml, Gibco #15750-078).

2.5. Lentivirus-mediated knockdown of KRAS using inducible shRNA
Dox-inducible lentiviral shRNA targeting human KRAS (TRE-shKRAS-IRES-Puro [in short: TetON-shKRAS]; PGK-rtTA3 in pLKO lentivirus vector) (Shao et al., 2014) was received as a
generous gift from Dr. William C. Hahn (Dana-Farber Cancer Institute and Broad Institute of
Harvard). For transfection, 3.5 x106 HEK 293T cells were plated overnight and transfected using
standard Calcium Phosphate transfection protocol. Media was changed the following day, and
virus was collected and filtered after 48 and 72 hours of transfection. For infection, human
pancreatic cancer cells: AsPC-1 and MIA PaCa-2 were plated at a density of 5 x 106 in 10 cm dish
overnight. The next day, the cells were infected with the freshly collected virus supplemented
with 8 µg/ml polybrene. Media was changed the following day. The infected cells were then
selected with puromycin at 2 µg/ml concentration for at least 10 days. 2 µg/ml of Doxycycline
was used for the induction of KRAS specific shRNA expression and knockdown of KRAS.
(The TRC ID and more information about the inducible shRNA against KRAS used in this study
can be found at: http://www.broadinstitute.org/rnai/public/clone/details?cloneId=TRCN0000010369).

2.6. Histology and immunostaining:
Immunohistochemistry and immunofluorescence staining on histological sections were performed
according to the following procedure: slides containing tissue section (5 µm thick) were
rehydrated in a sequential passage of solutions starting with xylene for 10 minutes (x3), 100%
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ethanol for 3 minutes (x2), 95%, 90%, 70%, 50% and 30% ethanol for 3 minutes each followed
by immersion in 1X PBS for 3 minutes. For IHC only, slides were incubated in 3% Hydrogen
Peroxide (H2O2) in methanol for 30 minutes at room temperature followed by incubation in 1X
PBS for 5 minutes (x2). Antigen retrieval was performed by adding 1mL of antigen unmasking
solution (Vectastain, Cat# H-3300, Vector Laboratories, Burlingame, CA) per 100 mL of dH2O.
The slides were completely immersed in antigen unmasking solution was first pre-heated at high
heat in microwave until boiling (approximately 2-4 minutes) and then it was boiled at ‘low-heat’
setting in microwave for 10 minutes. Slides were allowed to gradually cool to room temperature
for at least 30 minutes before washing it with 1X PBS (x3). Slides were then blocked with 5%
goat serum in 1X PBS and incubated at room temperature in a moist-chamber for at least 1 hour
before covering the section with primary antibodies prepared in 3% BSA in 1X PBS. Slides
covered with primary antibodies were incubated at 4oC overnight in a moist chamber. The next
day, slides were washed with 1X PBS for 5 minutes (x3). Secondary antibodies were then diluted
in 3% BSA at 1:200 for biotinylated antibodies (IHC) or at 1:1000 for fluorophore-conjugated
antibodies (IF) and incubated for 1 hour at room temperature in a moist chamber (in dark for IF
staining). For IHC staining, slides were washed with 1X PBS for 5 minutes (x3) and then
incubated with Avidin-Biotin Complex (Vectastain ABC reagent, Vector Laboratories,
Burlingame, CA) for 30 minutes as per the manufacturer’s instruction. Slides were then rinsed
with 1X PBS for 5 minutes (x3) and incubated with peroxidase substrate solution (Vector
Laboratories, Burlingame, CA) until the desired staining reaction was developed. Hematoxylin
staining was used as a counter-staining of the slides. Slides were later mounted using Permount
(Fisher Scientific, Hampton, NH) after complete dehydration of slides by gradual passage of
slides from 1X PBS to histoclear (xylene) in a reverse order mentioned earlier for rehydration of
slides. For mounting IF stained slides, stained slides were washed with 1X PBS for 5 minutes
(x3) followed by a single wash with distilled water for 5 minutes, and then mounted with
Vectashield mounting medium containing DAPI (Vector Laboratories, Burlingame, CA).
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The list of primary antibodies used for immunofluorescence and immunohistochemistry
are mentioned in Table 2.2. For the purpose of immunofluorescence staining, fluorescent
conjugated secondary antibodies were purchased from Invitrogen Corporation, and DAPI
purchased

from

Vector

Laboratories

was

used

as

nuclear

counter

stain.

For

immunohistochemistry, biotinylated secondary antibodies along with the Vectastain Elite ABC
kits were purchased from Vector Laboratories. Terminal deoxynucleotidyl transferase dUTP nick
end labeling (TUNEL) assay was done for detection of apoptotic cells using an in situ detection
kit (catalog# 03-333-566-001) from Roche Diagnostics following manufacturer’s protocol. All
the stained slides were imaged with an Axio Imager Microscope (Carl Zeiss Incorporation) or
LSM5 Pascal confocal microscope.

2.7. Western Blotting:
For immunoblotting analysis, cell lysates were prepared by lysing cell pellets in a buffer prepared
by mixing: 50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1mM EDTA, 1% NP-40, 0.5% Sodium
Deoxycholate, 0.1% SDS, 10 mM Sodium Fluoride, 1mM phenylmethyl sulfonyl fluoride, 0.4
units/mL Aprotinin, 0.1 mM Sodium Orthovandate, 1mM PMSF, 1 ug/mL Leupeptin. All the
samples for immunoblotting were processed at 4oC with extreme caution in the presence of the
above mentioned protease and lysosomal inhibitors. Whole cell extracts were run on Noves 420% Tris-glycine gradient gels and transferred to polyvinylidene difluoride (PVDF) membranes
(Life Technologies, Carlsbad, CA). Protein-transferred membranes were blocked for at least 1
hour in a solution of 1X Tris-buffered saline (TBS), 0.1% Tween-20, and either 5% bovine serum
albumin (BSA) or 5% non-fat dry milk. Blocked membranes were then covered with primary
antibody prepared in 5% BSA in 1X TBS buffer with 0.1% Tween-20 at an optimum dilution and
incubated at 4oC overnight with continuous shaking at low speed. The list of primary antibodies
used for immunoblotting are mentioned in Table 2.3. Membranes were then washed at least 3
times with washing buffer made of 1X TBS and 0.1% Tween-20, followed by an hour incubation
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with horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, Dallas,
TX) in 5% non-fat dry milk. Finally, the membranes were washed at least 3 times as described
before, followed by a single wash with 1X TBS without Tween-20 for 5 minutes. Protein bands
were detected using the electro-chemiluminescence (ECL) kit (GE Healthcare, Little Chalfont,
UK) according to the manufacturer’s protocol. For successive immunoblots, membranes were
subsequently stripped using 0.2 M Sodium Hydroxide solutions for 20 minutes. The protein
bands were quantified using ImageJ software (version 1.49v).

2.8. Quantitative Real-Time PCR (qRT-PCR)
Total RNA was extracted using the RNeasy mini kit (Qiagen #74104) following manufacturers’
instruction. 1-2 µg total RNA was used for cDNA synthesis using oligo-dT primers and the
SuperScript II first strand synthesis kit (Invitrogen #11904-018). Relative levels of mRNA were
determined by real-time quantitative PCR using the iQ-SYBR-Green Supermix (Bio-Rad #1708886). PCR was done using Hard-Shell PCR plates (Bio-Raf #HSP9611) in a CFX96TM RealTime System (Bio-Rad). Primers for mouse Igf1 and Actin, along with human IGF1 and GAPDH
were obtained from Integrated DNA Technologies (Coralville, IA, USA). Gene amplification was
done using PCR conditions: denaturation for 3 min at 95°C, followed by 39 repeated cycles of
denaturation at 95°C for 30 s, primer annealing at 60oC for 30s, and primer extension at 70°C for
30sec, and 10 min at 72°C. Primers used were as follows:

Gene

Sequence

Igf1 (mouse):

5’-CACCTCAGACAGGCATTGTGGATGA-3’ (FP)
5’-CACTCCTAA AGACGATGTTGGAATGT-3’ (RP)

Actin (mouse):

5’-TGGATGACGATATCGCTGCGC-3’ (FP)
5’-AAGCTGTAGCCACGCTCGGTC-3’ (RP)
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IGF1 (Human):

5’-AGTGCTGCTTTTGTGATTTCTTGAAG-3’ (FP)
5’-CTCTACTTGCGTTCTTCAAATGTACT-3’ (RP)

GAPDH (Human):

5’-GGTGAAGGTCGGAGTCAACG-3’ (FP)
5’-CTCAGCCTTGACGGTGCCATG-3’ (RP)

IGF1 gene expression data were normalized against either Actin (mouse) or GAPDH
(human) as an internal control using the 2–ΔΔCt method and expressed as arbitrary units. Sample
analysis was performed in triplicate with reproducible results. The data is represented as
represented as mean ± SEM.

2.9. Transcriptome analysis using RNA-Seq:
Total messenger RNA was extracted from flash-frozen, orthotopically transplanted pancreatic
tumor tissues from mice using RNeasy Mini Kit (Qiagen). First-strand cDNA synthesis was done
using Super-Script II from Invitrogen with oligo-dT primers according to manufacturer’s
protocol. Only good quality RNA samples with RNA integrity number (RIN) score of more than
8 were processed using the TruSeq RNA sample preparation kit and sequenced using a
HiSeq2000 Sequencer (Illumina) after performing a quality check using a Bioanalyzer-2100.
Paired-end sequencing was performed for KRAS-induced pancreatic samples, whereas single-end
sequencing was performed on c-MYC induced pancreatic tumor tissues. Differential gene
expression analysis was done using the Tuxedo package (Tophat, Cufflinks, and Cuffdiff). Gene
Set Enrichment Analysis (GSEA) was performed to identify the pathway enrichment in
pancreatic tumors in the presence or absence of oncogenic KRAS or c-MYC. Broad Institute’s
Integrative Genomics Viewer (IGV 2.3.63) was used to visualize the expression of candidate
genes.
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2.10. Flow cytometry analysis of cell death:
GFP positive regions of tumor were first isolated under fluorescent stereoscope (Axiovert 35,
Carl Zeiss Incorporation) to ensure the isolation of tumor cells. Single cells from the tumor
tissues were isolated using the digestion and isolation protocol mentioned above. Cells were
stained with primary antibodies after blocking the cells with 2% FBS in 1X Hank’s Balanced Salt
Solution (HBSS) for 30 minutes on ice. Biotinylated anti-CD31 (BD Pharmingen #553371) and
anti-CD45 (BD Pharmingen #553078) antibodies were used for the elimination of endothelial and
hematopoietic lineages respectively using AutoMACS Pro (Miltenyi Biotec). Fluorochrome (PE)
conjugated AnnexinV (BD Pharmingen #556422) was used for staining single cells. Only the
GFP positive cancer cells were taken into consideration for analysis of apoptotic cells. Data were
acquired from stained cells using BD FACSCalibur flow cytometer. All the acquired data were
analyzed using FlowJo v9.8 software (Tree Star Incorporation).

2.11. Orthotopic and subcutaneous tumor transplantation:
Freshly isolated or viably frozen pancreatic tumor samples from transgenic mice were first
washed in 1x PBS followed by DMEM containing 10% FBS in aseptic condition. Tumor tissues
were then cut into small pieces of 1-2 mm in diameter, and single piece from a tumor was
transplanted orthotopically into normal pancreatic tissues of 6-8 week-old athymic nude mice.
For the purpose of subcutaneous transplantation, 1 million tumor cells in DMEM (10%FBS) were
mixed with matrigel (BD Biosciences, #356231) in 1:1 proportion and injected into the right
flank under the skin.

2.12. In vivo inhibitor treatment:
For inhibitor treatment, mice with tumor (approx. 10 mm in diameter) were kept on Doxycycline
for 2 weeks for the complete regression of the palpable tumor. Complete regression of the tumor
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and down-regulation of the transgene were confirmed by palpation and by in vivo
bioluminescence (luciferase) imaging respectively. Mice with regressed tumors were then treated
with DMSO or IGF-1R inhibitor (Linsitinib/OSI-906; ChemieTek LLC, Indianapolis, IN;
50mg/kg via oral gavage once daily for 5 consecutive days) along with Doxycycline for an
additional week. Both DMSO and inhibitor were discontinued the following week, and tumor
volumes were measured on a weekly basis for 4 successive weeks. Tumor volumes were
calculated using the formula: V=(l2 x w)/2 (where l is length and w is width).

2.13. Statistical analysis:
All the graphic illustrations and statistical tests were performed using Prism-6 software
(GraphPad Software, Inc., La Jolla, CA). Data are expressed as mean ± standard error of mean
(SEM) unless otherwise mentioned and were compared using an unpaired student t- test. P value
less than 0.05 was considered statistically significant.
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Table 2.1. List of PCR primers, sequences and cycling conditions for mouse genotyping
Gene

Primer Sequence (5’ to 3’)

Cycling Conditions

Pdx1-Cre

CTGGACTACATCTTGAGTTGC

96oC 3min

GGTGTACGGTCAGTAAATTTG

96oC 1 min, 55oC 1 min, 72oC 1min
72oC 5 min

CAG-βgeo-tTA

GGCTCTAGAGCCTCTGCTAACC

96oC 3 min

CTTCGCTATTACGCCAGCTGG

96oC 1 min, 55oC 1 min, 72oC 1min
72oC 5 min

TetO-KRASG12D

GCCTGCGACGGCGGCATCTGC

96oC 3 min

GGGAATAAGTGTGATTTGCCT

96oC 1 min, 55oC 1 min, 72oC 1min
72oC 5 min

TetO-Luciferase

CCGTCAGATCGCCTGGAGACG

96oC 3 min

GGCGGATGGTCTCCACTTCGC

96oC 1 min, 55oC 1 min, 72oC 1min
72oC 5 min

TetO-H2B-GFP

TACAACAAGCGCTCGACCATCAC

96oC 3 min

CCGTCCAGCTCGACCAGGATGG

96oC 1 min, 55oC 1 min, 72oC 1min
72oC 5 min

CAG-GFP

CAGTCAGTTGCTCAATGTACC

96oC 3 min

ATATCACCAGCTCACCGTCTT

96oC 1 min, 55oC 1 min, 72oC 1min
72oC 5 min

Cdkn2a

Generic Cre

GTGATCCCTCTACTTTTTCTTCTGACT

96oC 3 min

GAGACTAGTGAGACGTGCTACTTCC

96oC 1 min, 55oC 1 min, 72oC 1min

CGGAACGCAAATATCGCAC

72oC 5 min

TGCCTGCATTACCGGTCGATGC

96oC 3 min

CCATGAGTGAACGAACCTGGTCG

96oC 1 min, 55oC 1 min, 72oC 1min
72oC 5 min
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Table 2.2. List of primary antibodies used for IHC and IF stainings
Antibody

Supplier

Catalog Number

Host Animal

α-SMA

Sigma

A5228

Mouse

AMYLASE

Sigma

A8273

Rabbit

c-MYC

Abcam

ab32072 (Y69)

Rabbit

CK-19

Iowa Hybridoma

Troma III

Rat

Cleaved-CASPASE-3

Cell Signaling

8202S

Rabbit

E-CADHERIN

BD Biosciences

610181 (Clone 36)

Mouse

GFP

Aves Laboratories

GFP-1020

Chicken

HER2

Abcam

ab2430

Rabbit

IGF1

Abcam

ab9572

Rabbit

Ki67

Abcam

ab16667

Rabbit

MUC1

Abcam

ab15481

Rabbit

MUC5AC

Abcam

ab3649

Mouse

pAKT (T308)

Cell Signaling

13038S

Rabbit

pMAPK (pERK1/2)

Cell Signaling

4370S

Rabbit

pIGF-1R (Y1161)

Abcam

ab39398

Rabbit

pSTAT3 (Y705)

Cell Signaling

9145S

Rabbit

SOX9

Millipore

AB5535

Rabbit
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Table 2.3. List of primary antibodies used for western blotting
Antibody

Supplier

Catalog Number

Host Animal

α-TUBULIN

Epitomics

ab52866

Rabbit

BAD (Mouse)

Santa Cruz

sc-943 (C-20)

Rabbit

BAD (Human)

Santa Cruz

sc-8044

Rabbit

BIM

Abcam

ab7888

Rabbit

c-MYC

Abcam

ab32072 (Y69)

Rabbit

CK-19

Iowa Hybridoma

Troma III

Rat

Cleaved CASPASE-3

Cell Signaling

8202S

Rabbit

KRAS

Proteintech

12063-1-AP

Rabbit

MDM2

Santa Cruz

sc-965

Mouse

p19-ARF

Abcam

ab80

Rabbit

p53

Santa Cruz

FL-393/sc-6243

Rabbit

pAKT (T308)

Cell Signaling

13038S

Rabbit

PARP

Cell Signaling

9532

Rabbit

pBAD (Ser136)

Abcam

ab28824

Rabbit

pBIM (Ser87)

Bioss Antibodies USA

bs-3012R

Rabbit

PDGFRβ (Μouse)

Cell Signaling

3175S

Mouse

PDGFRβ (Ηuman)

Cell Signaling

3169S

Rabbit

Cell Signaling

4370S

Rabbit

pIGF-1R (Y1135)

Cell Signaling

3918S

Rabbit

pS6 (S240/244)

Cell Signaling

5364S

Rabbit

pMAPK/pERK1/2
(T202/Y204)
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Chapter 3: Results*
*Results described in this chapter were generated with the collaborative effort of Rajbhandari N,
Lin WC, Wehde B, Triplett AA, and Wagner KU. A part of the work described in this chapter
has been submitted for publication under the title: Autocrine IGF1 signaling mediates
pancreatic tumor cell dormancy in the absence of oncogenic drivers.
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3.1. Introduction:
Pancreatic ductal adenocarcinoma (PDAC) remains a largely incurable fatal disease and is
predicted to become the second deadliest cancers in the United States by 2030 (Rahib et al.,
2014). Pancreatic cancers harbor a number of well-characterized signature mutations involving
the KRAS oncogene and the CDKN2A, TP53, and SMAD4 tumor suppressor genes (Eser et al.,
2013; Eser et al., 2014; Hingorani et al., 2003; Hruban et al., 2000; Shah et al., 2007). Activating
mutations in KRAS are present in the majority of human PDAC cases. Genetically engineered
mouse (GEM) models have demonstrated the essential role of oncogenic KRAS, along with
deficiencies of the other aforementioned tumor suppressors, in the initiation of PDACs (Aguirre
et al., 2003; Hingorani et al., 2003). We have previously reported that c-MYC, a critical
downstream effector of KRAS, is also overexpressed in many cases of human cancer and in
KRAS-induced pancreatic precursor lesions and invasive tumors in mice. Using a genetically
engineered model we previously reported that upregulation of c-MYC in pancreatic progenitors is
entirely sufficient to induce metastatic pancreatic adenocarcinoma after a short latency (Lin et al.,
2013). Moreover, persistent expression of c-MYC is required for cancer cell survival at primary
and metastatic sites, indicated by the dramatic shrinkage of big palpable tumor upon
downregulation of c-MYC. This finding from our mouse model of pancreatic cancer provides a
strong rationale for the development of targeted therapies against the oncogenic driver for the
treatment of pancreatic cancers. However, despite this compelling evidence from the c-MYC
induced pancreatic cancer model, the rationale for developing a targeted therapy against mutant
KRAS or its effector is not strongly justified because of the lack of evidence suggesting the
essential role of oncogenic KRAS in pancreatic cancer maintenance. Our current study is
therefore, focused to address the role of mutant KRAS in initiation and maintenance of pancreatic
cancer, with an aim of testing the suitability of the KRAS-oncogene as a potential therapeutic
target to treat human pancreatic cancer.
Despite the exciting potential of a targeted therapy for the treatment of different type of
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cancers, it is a clinical reality that tumors relapse following successful remission, which indicates
that a few tumor cells can survive in absence of oncogenic signals and are responsible for later
recurrences (Holohan et al., 2013). In line with this notion, we previously demonstrated in our
reversible c-MYC-induced tumor model that despite the complete macroscopic remission of
primary and metastatic pancreatic tumors in response to the ablation of c-MYC, a few residual
cancer cells were able to survive and remain dormant, and were the cellular basis of tumor
recurrence upon c-MYC reactivation (Lin et al., 2013). However, neither the detailed mechanisms
nor the molecular signaling network regulating the survival of these residual cancer cells in vivo
have been explored in detail previously. Here, in this study we have attempted to determine the
molecular mechanism of the survival of the few cancer cells on sustained ablation of oncogenic
drivers (c-MYC and KRASG12D) that would result in tumor relapse upon getting favorable
signaling cues.
In this chapter, I report the generation of a novel in vivo model of reversible PDAC that
expresses oncogenic KRAS in a temporally controlled manner in normal and neoplastic
pancreatic ductal cells of adult transgenic mice that are haploinsufficient in Cdkn2a. I will
demonstrate how our unique model allows us to examine the biological relevance of mutant
KRAS during all stages of pancreatic cancer progression. I will also demonstrate how I have
identified, isolated and characterized rare tumor cells after disease remission using genetically
labeled tumor cells. Using genome-wide transcriptome analyses in two different (KRASG12D and
an additional c-MYC induced) pancreatic cancer models, we show that the activation of autocrine
IGF1 signaling and the downstream activation of AKT is a common mechanism that mediates the
survival of residual cancer cells following the ablation of KRASG12D and c-MYC as oncogenic
drivers. I also validated these findings from animal models of PDAC in 2 different human
pancreatic cancer cell lines by conditional knockdown of KRAS. In conclusion, all the data
presented in this chapter strongly favors development of targeted therapies against the oncogenic
drivers for the successful treatment of advanced-stage pancreatic cancer. However, our current
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study also strongly suggests the importance for the development of an adjuvant therapeutic
strategy targeting the IGF1R/AKT pathway in addition to the oncogenic drivers to effectively
eliminate residual cancer cells and to prevent pancreatic cancer recurrence.
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3.2. Results:
Generation of genetically labeled pancreatic tumor model system with spatially and
temporally regulated expression of oncogenic KRAS in exocrine pancreas
To study the role of an oncogene during initiation and progression of pancreatic cancer, our lab
employed a novel tetracycline-responsive (tet-responsive), reversible tumor model system, where
the expression of the oncogenic c-MYC can be controlled spatially and temporally by the
administration of doxycycline (Lin et al., 2013) [further details on the mechanism of action of tetresponsive systems (both tet-on and tet-off) can be found in an excellent review by Mark
Lewandosky (Lewandoski, 2001)]. In this study, we have used a similar tumor model of targeted
therapy to understand the role of oncogenic KRAS (KRASG12D) in pancreatic cancer maintenance
in mice (Pdx1-Cre/CAG-βgeo-tTA/TetO-KRASG12D) (Figure 3.1). Cre recombinase under the
regulation of the Pdx1 promoter initiates a constitutive expression of the tetracycline-controlled
transactivator (tTA) in pancreatic progenitors and their descendants. Thus, the tTA is expressed in
mouse pancreatic epithelium during embryogenesis and throughout adulthood. The pancreasspecific expression of the tTA, consequently induces the activation of TetO-driven responder
transgenes encoding the gain of function mutant KRAS (KRASG12D) as well as the luciferase
reporter (TetO-Luc). The expression of these responder genes is precisely and temporally
regulated in these transgenic mice by administration of doxycycline (Dox) in the drinking water.
These transgenic mice were also crossed to CAG-LSL-GFP reporter mice to genetically label and
enable the tracking of normal as well as pancreatic cancer cells at primary and metastatic sites.
Hereafter, our quintuple transgenic mice (Pdx1-Cre/CAG-tTA/TetO-KRASG12D/CAG-GFP/
TetO-Luc) are referred to as Kras*.
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Exogenous expression of oncogenic KRAS in mouse pancreas induces pancreatic ductal
lesions resembling the human disease
To closely mimic the physiological context of KRAS mutation in human disease, along with the
aversion of any possible adverse consequences of overexpression of oncogenic KRAS during
embryonic development, we maintained the parental animals and the nursing offspring
continuously on Dox until postpartum day 10 (P10). This approach has already been validated to
turn off the TetO-driven transgenes by passive transmission of Doxycycline to the fetus and
nursing pups from mother (Lin et al., 2013). Following the activation of oncogenic KRAS at 10
days of age, after withdrawal of Dox water from the nursing mothers, the Kras* mice developed
distinct PanIN lesions as early as 8 weeks of age. Low to mid-grade PanIN lesions were
unequivocally present in Kras* mice at 12 weeks of age (Figure 3.2A). The histological features
of PanIN lesions in our Kras* mice resembled classic human pre-neoplastic lesions with a
characteristic ductal features indicated by their histological appearance and positive staining with
the ductal marker- cytokeratin 19 (CK19) (Figure 3.2B).

All the pre-neoplastic lesions

demonstrated an increase in phospho-MAPK, indicative of active RAS signaling and markedly
increased proliferation indicated by increased Ki-67+ cells (Figure 3.2C and D). In contrast, none
of the double transgenic control littermates (CAG-tTA/TetO-KRASG12D) developed any
neoplastic lesions. Consistent with the previously established role of KRASG12D in PDAC
initiation (Hingorani et al., 2003), our Kras* mice demonstrated a potential to initiate classical
pancreatic precursor lesions recapitulating the human PanIN lesions.

Oncogenic KRAS is required for the maintenance of early pre-neoplastic ductal lesions
Since exogenous expression of KRASG12D was sufficient to induce pre-neoplastic lesions in our
Kras* mice, we decided to assess the role of oncogenic KRAS in the maintenance and
progression of PanINs. To experimentally address this, we kept 12 weeks old Kras* mice on Dox
for 7 days to allow sufficient time for the downregulation of oncogenic KRAS and for tissue
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remodeling. Pancreatic tissues were collected from Dox untreated and treated Kras* mice after 7
days. The downregulation of oncogenic KRAS upon Dox treatment was confirmed by decrease in
phospho-ERK1/2 through immunoblot (Figure 3.3A and B). Histological examination of
pancreata revealed little or no evidence of PanIN lesions after 7 days of Dox treatment (Figure
3.3C, top), with the re-population of acinar cells in place of ductal lesions after downregulation of
KRASG12D. The transformed ductal cells also stopped proliferating after downregulation of KRAS
signaling, which was indicated by the significant decrease in number of Ki67+ cells (Figure 3.3C,
bottom). These data altogether indicated the reversal of PanINs upon downregulation of
KRASG12D, highlighting the requirement of oncogenic KRAS in PanIN maintenance in mice.

Downregulation of oncogenic KRAS results in rapid regression of pancreatic tumors
PanIN lesions only occasionally progress to invasive PDAC with a very long latency (3 out of 11
mice at 18 months) in the transgenic mice highlighting the requirement for additional genetic
events to promote pancreatic cancer (Collins et al., 2012a; Hingorani et al., 2003). To expedite
the malignant progression, and to address the tumor maintenance role of oncogenic KRAS in
advanced stage cancers, we crossed our conditional Kras* mice with the conventional Cdkn2a
knockout mice. Kras* Cdkn2a+/- mice succumbed to pancreatic cancer between 52 to 81 weeks
(median survival 468 days), in contrast to Kras* Cdkn2a-/- mice that developed ductal tumors
more rapidly between 11 and 15 weeks of age (median survival 95 days) (Figure 3.4). The Kras*
Cdkn2a mutant tumors very closely resembled the human PDACs with characteristic glandular
appearance with increased stromal components, inflammatory response and mucin expression
(Figure 3.5). We also observed frequent metastasis to distant organs like liver and lungs (Figure
3.6A and B). The molecular analysis of primary pancreatic tumors from Kras* Cdkn2a+/- mice
revealed that tumor progression was associated with the loss of expression of the Cdkn2a wildtype allele and an upregulation of MDM2 (Figure 3.7), suggesting that the extended survival of
Kras* Cdkn2a+/- mice is due to tumor suppressive functions of p16Ink4a and p19Arf encoded by the
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Cdkn2a wild-type allele.
In order to test the requirement of oncogenic KRAS in invasive PDAC three 12 month
old Kras* Cdkn2a+/- mice with palpable pancreatic tumors were kept on Dox for 2 weeks for
KRASG12D inactivation. Following the downregulation of oncogenic KRAS, palpable tumors in
all the experimental mice completely regressed to a readily non-palpable state. A closer
examination of pancreatic sections revealed degeneration and loss of tumor cells with the
accumulation of fibrotic tissues surrounding the remnant ductal structures, however the pancreata
did not return into their normal morphology. The extinction of oncogenic KRAS in regressed
tumors after Dox treatment was accompanied by a decrease in phosphorylated ERK1/2 along
with significantly reduced tumor cell proliferation (Figure 3.8). Collectively, these findings
strongly indicate that KRASG12D is required for the maintenance of PDAC in mice by affecting
proliferation and viability of tumor cells.

Few cancer cells survive oncogenic KRAS ablation and facilitate rapid tumor recurrence
In our previous study using a similar ligand-controlled c-MYC-induced pancreatic tumor model,
we had successfully demonstrated that a few cancer cells could survive for a protracted period of
time without the requirement of the tumor initiating oncogene (Lin et al., 2013). Also, drug
resistance and tumor recurrence after an early positive response is a common problem associated
with many human cancers. Thus, the knowledge from our previous in vivo study and from many
other clinical observations encouraged us to investigate whether down-regulation of oncogenic
KRAS signaling would be sufficient for the complete elimination of pancreatic cancer cells.
Even though the primary pancreatic tumors regressed macroscopically upon KRASG12D
downregulation in our Kras* Cdkn2a mutant mice, it was difficult to assess whether all the
neoplastic cells had undergone apoptosis in our autochthonous model mainly because of 3
reasons: first, all of the tumor cells as well as normal pancreatic epithelial cells were genetically
labeled (GFP), which made it difficult to distinguish normal epithelial cells from tumor cells upon
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regression. Second, widespread expression of KRASG12D in the pancreata of transgenic mice
resulted numerous PanIN lesions with multifocal disease onset, which made it virtually
impossible to discriminate residual cancer cells from pre-neoplastic cells following the
downregulation of oncogenic KRAS. Third, it was difficult to address whether the recurrence of
the tumor after reactivation of oncogenic KRAS was due to the proliferation of the pre-existing
residual cancer cells or due to the de novo transformation of previously untransformed normal
pancreatic epithelial cells in this model. Therefore, to experimentally examine whether some
pancreatic cancer cells survived upon ablation of oncogenic KRAS, we used a unique approach of
orthotopic transplantation of GFP-labeled cells into wild-type recipient athymic nude mice. This
technique allowed us to easily distinguish the few residual cancer cells in a wild-type pancreatic
background upon the tumor regression following oncogenic KRAS ablation. At the same time,
this unique approach would also help us rule out the recurrence of tumor by de novo
transformation of previously untransformed normal cells upon KRAS re-induction.
Before testing whether some pancreatic cancer cells survived without the presence of
oncogenic KRAS, we first verified that our orthotopic tumor transplantation model exactly
mimicked the autochthonous tumor model. For this, we established a cohort of athymic nude
mice that developed secondary tumors following orthotopic transplantation of primary pancreatic
tumors from Kras* Cdkn2a-/- mice (Figure 3.9). The expression of oncogenic KRAS and the
growth of tumors in recipient mice were indirectly assessed by in vivo bioluminescence imaging.
Following the identification of tumors, we treated the tumor bearing recipient mice with Dox and
the tumor size was measured at different time points for 7 days. Tumor size comparison and
histological examination of pancreatic tissues indicated that Dox administration for just 7 days
was sufficient to induce a remarkable regression of the tumor (Figure 3.10A). We directly and
indirectly confirmed the down-regulation of oncogenic KRAS upon Dox treatment by in vivo
luciferase imaging and immunoblotting respectively (Figure 3.10B and C). We also found a
substantial increase in the number of apoptotic cells (cleaved caspase-3 positive) upon acute
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down-regulation of oncogenic KRAS, suggesting that the apoptosis mediated death of cancer
cells was responsible for the tumor regression (Figure 3.11). Collectively, all of the evidences
from the orthotopic transplantation model clearly prove that the growth, proliferation and survival
of the majority of the KRASG12D induced pancreatic cancer cells were dependent upon the
continuous expression of oncogenic KRAS. Also, this validated that the orthotopic
transplantation model can clearly serve as a good surrogate for the autochthonous model for the
study of tumor progression and maintenance.
To experimentally determine whether any pancreatic cancer cells had survived without
the oncogenic KRAS, we next established a cohort of wild-type recipient mice that developed
secondary lesions following the transplantation of viable fragment of pancreatic tumors from
Kras* Cdkn2a-/- mice. Once the tumor size reached approximately 10 mm in diameter, we treated
the tumor bearing recipient mice for as long as 8 weeks with Dox until the tumors had regressed.
The subsequent withdrawal of Dox from the drinking water led to a gradual reactivation of
oncogenic KRAS, resulting in a rapid recurrence of tumors in all experimental animals (Figure
3.13A). Because of the rapid reappearance of the tumor after withdrawal of Dox was highly
unlikely due to a de novo transformation of normal pancreatic cells, it was evident that a few
cancer cells had survived without the KRASG12D, and these residual cells served as cancerinitiating cells on re-expression of KRASG12D.
Interestingly, closer examination of the pancreas in tumor bearing mice before and after
Dox treatment revealed the presence of GFP-labeled cancer cells in regressed tumors (Figure
3.12B), indicating that the vast majority of, but not all, cancer cells died following
downregulation of oncogenic KRAS. A closer examination of the histological sections revealed
that the GFP labeled residual tumor cells did not express oncogenic KRAS indicated by
downregulation of phospho-ERK (Figure 3.12C). Also, residual cancer cells did not proliferate,
and undergo any form of cell death, which was indicated by the absence of both Ki-67 and
TUNEL staining (Figure 3.13). The fact that residual cancer cells were still identifiable in mice
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that were continuously treated with Dox for 4 weeks clearly indicates that a small subset of
cancer cells remained dormant without the expression of KRASG12D. Our result strongly
suggested that these residual cancer cells could serve as a reservoir for tumor recurrence upon reexpression of oncogenic KRAS.

IGF1 signaling pathway is upregulated in residual cancer cells following oncogenic KRAS
ablation
To identify the molecular mechanism(s) having a possible role in cancer cell survival in the
absence of KRASG12D, we a performed genome-wide transcriptome analysis (RNA-Seq) on bulk
tumor cells and GFP-positive residual cancer cells. The possibility of tetracycline-transactivator
(tTA) independent or compensatory upregulation of endogenous KRAS in Dox-treated, regressed
tumors was ruled out by direct visualization of the decreased expression of Kras transcripts in
Dox-treated tumor samples (Figure 3.14). Gene set enrichment analysis (GSEA) (Subramanian et
al., 2005) on transcriptomics data identified significant alteration in the expression of wide range
of obvious and previously validated gene sets and pathways, i.e., MAP kinase signaling
pathways, pancreatic cancer, gene sets associated with O- and N-glycosylation pathways (Figure
3.15). This also ensured that the samples that were used for identification of enriched pathways
were of good quality, and hence the pathways identified by GSEA could be well trusted with high
confidence.
Further, in depth assessment of enriched pathways discovered the insulin-like growth
factor-1 (IGF1) pathway as the one of the major pathways that was significantly enriched in the
KRAS-ablated regressed tumors (Figure 3.16A-C). In accordance with GSEA’s finding, we found
that the expression of the Igf1 transcript was persistently up regulated in all of the regressed
tumor samples analyzed (Figure 3.16D and E). Because IGF-1R/AKT signaling has been
demonstrated to be responsible for the survival of various cancer cells, e.g. along with melanoma
cells upon inhibition of oncogenic signaling using a BRAF inhibitor (Villanueva et al., 2010), we
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decided to further investigate the functional role of IGF-1/IGF-1R signaling in pancreatic cancer
cells.
To experimentally confirm that IGF1 signaling is upregulated in residual cancer cells we
performed immunostaining for activated IGF-1R (pY-IGF-1R) in primary and regressed tumor
samples (n=3). Consistent with our RNA-Seq data, we found that the expression of phospho-IGF1R was substantially increased in regressed tumors, and was exclusively restricted to the tumor
cells (Figure 3.17). Our data thus indicated a compensatory upregulation of IGF-1R signaling in
residual cancer cells in response to KRASG12D ablation.

IGF1 signaling promotes survival of dormant cancer cells by inactivation of pro-apoptotic
members of the BCL-2 gene-family and stabilization of anti-apoptotic XIAP via AKT
mediated phosphorylation
To determine the functional implication of upregulated IGF-1 and its receptor activation during
ablation of oncogenic KRAS in pancreatic cancer in mice, we performed an immunoblot analysis
for the effectors downstream of IGF-1R. We observed significantly increased phosphorylated
AKT in residual tumors (Figure 3.18); supporting the idea that IGF-1R/PI3K/AKT pathway is
upregulated in residual cancer cells upon KRASG12D inhibition. Further, considering the role of
IGF-1R and PI3K/AKT pathway in cell survival, we next examined downstream phosphorylation
targets of AKT. Among the many substrates of AKT that are known to be involved in cell
survival we considered analyzing three potential candidates, which included pro-apoptotic BAD
and BIM, and anti-apoptotic XIAP (X-linked inhibitor of apoptosis). BAD and BIM are known to
bind and inactivate the prosurvival factors BCL-XL and BCL-2 when unphosphorylated and
induce apoptosis. However, when AKT phosphorylates Serine 136 (S136) and Serine 87 (S87) of
BAD and BIM respectively, it promotes their association with the 14-3-3 protein and subsequent
sequestration in the cytoplasm (Datta et al., 1997; Downward, 1999; Qi et al., 2006). Consistent
with this idea we found that the phosphorylated form of both BAD and BIM were increased along
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with their total level, suggesting that the increased pro-apoptotic BAD and BIM were rendered
ineffective to induce tumor cell death due to AKT mediated phosphorylation. On the other hand,
despite a modest difference in the level of anti-apoptotic protein XIAP at the transcript level (data
not shown), we observed a significantly increased level of the XIAP at the protein level (Figure
3.18A and B). This result indicated that XIAP is most likely regulated at the post-transcriptional
level. Consistent with this, AKT-phosphorylated XIAP was significantly increased in the residual
tumors. Phosphorylation of XIAP by AKT protects XIAP from ubiquitination and degradation
(Dan et al., 2004). Collectively, our results suggest that the upregulated IGF-1R/PI3K/AKT
pathway in residual cancer cells promote their survival in the absence of the oncogenic KRAS by
AKT mediated phosphorylation and neutralization of antiapoptotic BAD and BIM, and
stabilization of antiapoptotic XIAP.
Further, to test if the compensatory upregulation of IGF-1R signaling following
downregulation of oncogenic KRAS was a tumor-cell intrinsic property we generated 2
independent cell lines from tumors in Kras* Cdkn2a mutant mice which were highly responsive
to Dox treatment in vitro. The responsiveness of the cell lines to Dox treatment and
downregulation of the transgene was confirmed by absence of luciferase expression and
significantly decreased phospho-ERK1/2 in both cell lines (Figure 3.19A and B). The
downregulation of KRASG12D upon Dox treatment in vitro resulted in a visible change in
morphology of the cells from elongated fibroblast-like to more differentiated epithelial-like cells
(Figure 3.19C), but with markedly reduced apoptosis in comparison to in vivo. Dox-treated cells
in vitro behaved more like residual cancer cells in vivo, where the prolonged inhibition of
oncogenic KRAS over a period of 7 days resulted in decreased proliferation and a compensatory
increase in IGF-1R signaling indicated by increased phosphorylation of IGF-1R and AKT, along
with its downstream effectors BIM, BAD and the ribosomal protein S6 kinase (Figure 3.20).
Collectively, our in vivo and in vitro derived results revealed that downregulation of oncogenic
KRAS resulted in a compensatory activation of IGF-1R/AKT signaling in pancreatic cancer.
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Pharmacological inhibition of IGF-1R signaling affects the survival of residual cancer cells
and delays tumor recurrence upon KRAS reactivation
The activation of the IGF-1R/AKT pathway and the phosphorylation of pro-apoptotic
BCL-2

family

members

suggested

that

residual

cancer

cells

might

survive

by

phosphorylation/inactivation of pro-apoptotic molecules BAD and BIM. Therefore, we
hypothesized that the selective inhibition of the IGF-1R pathway with an inhibitor of IGF-1R
(Linsitinib/OSI-906) might affect their survival. To experimentally address if IGF-1R inhibition
acted in synergy with KRAS ablation in vivo, mice with regressed tumors were treated with
DMSO or Linsitinib for 1 week (50mg/kg/day for 5 consecutive days for a week) (Figure 3.21).
As expected, the acute treatment of mice bearing residual tumors resulted in dramatic decrease in
phosphorylation of IGF1 receptors with the resultant decrease in phosphorylation of downstream
AKT. This decrease in phosphorylation of the IGF1 receptor and AKT was accompanied by
increased cancer cell death (Figure 3.22). Additionally increased cell death due to direct
inhibition of IGF-1R pathway was confirmed by flow-cytometry (Figure 3.23A and B). To our
surprise, we also observed a significant increase in total IGF1 receptor levels in Linsitinib treated
tumor samples, indicating a compensatory upregulation of the receptor. This further highlighted
the important role of the IGF-1R/AKT signaling pathway for the survival of residual cancer cells
in absence of oncogenic KRAS. More excitingly, despite a relatively short treatment, Linsitinib
significantly delayed the recurrence of tumors within the pancreas of recipient mice (Figure
3.23C). At the same time Linsitinib improved the relapse-free survival of tumor bearing mice
(mean 49 days; median 49 days; maximum 72 days) in comparison to the control mice (mean 38
days; median 41 days; maximum 51 days) after withdrawal of Dox and inhibitor (Figure 3.23D).
All these data from our in vivo studies suggested that the survival of a significant subset of
residual cancer cells in absence of oncogenic KRAS was dependent on IGF-1R signaling. In other
words, inhibition of KRAS along with the IGF-1R pathway could serve as a suitable therapeutic
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strategy for the effective prevention or delay in the pancreatic tumor recurrence in oncogenic
KRAS-driven tumors.

Exogenous overexpression of wild-type IGF-1 receptor prevents tumor regression upon
ablation of oncogenic KRAS
We identified an increased IGF1 signaling in the residual cancer cells, and experimentally
demonstrated that the pharmacological inhibition of IGF-1R signaling can significantly delay the
recurrence of the KRASG12D-induced cancers. However, to rule out any possibility that the
impedance of tumor growth and recurrence was not due to an off-target effect of the inhibitor, we
carried out a genetic approach to alternatively demonstrate that forced activation of IGF-1R
signaling can rescue tumor regression in the absence of KRASG12D. To determine if forced
activation of IGF-1R signaling can rescue KRASG12D dependence, we derived two wildtype IGF1
receptor (pBabe-IGF-1R) expressing and isogenic control pancreatic cancer cells from Kras*
Cdkn2a mutant mice (Figure 3.24A). IGF-1R–expressing cancer cells formed tumors only
marginally faster than the control cells, indicating the wildtype receptor did not provide a
significantly added growth advantage. However, following Dox treatment, control tumors
underwent a quick and dramatic regression, whereas IGF-1R-transduced tumors showed only an
early marginal regression and remained static throughout the treatment duration suggesting that
overexpression of wild-type IGF-1R was sufficient to partially rescue the loss of oncogenic
KRAS (Figure 3.24B). As all the isogenic cancer cells co-expressed TetO-driven KRASG12D and a
luciferase reporter, the absence of luciferase expression in Dox-treated IGF-1R overexpressing
tumors indirectly confirmed that the prevention of complete tumor regression following Dox
treatment was not due to the Dox (tTA)-independent expression of KRASG12D (Figure 3.24C).
Biochemical analysis of control and IGF-1R overexpressing residual tumors following Dox
treatment confirmed the maintenance of IGF-1R signaling in the IGF-1R overexpressing tumors
(Figure 3.24D). Altogether, these data strongly confirmed that IGF-1R signaling is sufficient for
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the compensation of oncogenic KRAS for the cancer cell survival, despite being insufficient to
completely compensate for the mutant KRAS for tumor growth.

IGF-1R/AKT signaling mediates cancer cell dormancy in a c-MYC-driven reversible
pancreatic tumor model
We had identified and demonstrated the persistent activation of the IGF-1R/AKT pathway for the
survival of residual cancer cells in the absence of the oncogene in a KRASG12D-induced tumor
model. However, to address the broad applicability of our findings, we decided to assess whether
this mechanism of cancer cell survival was common to the tumors driven by other oncogenes
besides KRAS. We have previously demonstrated that the c-MYC protein is overexpressed in all
human pancreatic cancer cell lines irrespective of the KRAS mutation status. In the same study,
we also demonstrated for the first time that c-MYC can induce genuine PDACs in mouse (Lin et
al., 2013). Importantly, we were able to show that despite a macroscopically complete regression
of primary and metastatic tumors following the ablation of c-MYC, some cancer cells remained
dormant in a similar manner to the cancer cells in KRASG12D-induced PDACs. So we were placed
in a unique position to test our hypothesis in another unique model of PDAC.
To identify the common mechanism of survival of dormant cancer cells in the absence of
oncogenic c-MYC in our pancreatic cancer mouse model, we performed transcriptomic analysis
on a small group of tumor samples from bulk and regressed tumors. Direct comparison of the
change of gene sets between c-MYC overexpressing bulk tumor cells and their descendant
residual cancer cells after the downregulation of c-MYC showed the expected decrease in the
expression of genes associated with basal transcription factors, DNA replication, and the cell
cycle (Figure 3.25.A, B and C). A closer examination of individual genes revealed that residual
cancer cells from the c-MYC model show some striking similarities to the gene expression
profiles of dormant cancer cells from the KRAS-induced tumor model, specifically, Igf1 and Igf1r. We observed a substantially higher expression of Igf1 transcripts in regressed tumors in
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comparison to the c-MYC expressing bulk tumors (Figure 3.26A and B). Our finding from the
RNA-Seq data analysis was further supported by our observation of a strong and widespread
presence of phosphorylated IGF1 receptor in immunostained sections from a few randomly
selected regressed tumors (Figure 3.26C). To further validate that the IGF1 signaling upregulation
is a consistent phenomenon rather than a fortuitous observation during oncogene ablation in these
tumors, we performed immunoblot analysis and confirmed the consistent upregulation of the
IGF-1R/AKT pathway along with the phosphorylation of the downstream target XIAP (Figure
3.27A). Next, we used a pure tumor cell lines generated from c-MYC-induced pancreatic cancers
for testing the consequences of a conditional downregulation of c-MYC in vitro. As expected,
both acute (2 days) and prolonged (7 days) downregulation of c-MYC led to a dramatic
upregulation of IGF1 receptor phosphorylation and AKT activation (Figure 3.27B) in cultured
cells. Additionally, the total levels of the pro-apoptotic BCL2 family protein BAD, were reduced
in residual cancer cells. This strongly indicated that the upregulation of IGF-1R signaling upon cMYC downregulation was due to a tumor cell intrinsic mechanism.
To test and validate the importance of this finding in vivo, we subcutaneously
transplanted the cultured cells and examined the biochemical alteration in residual cancer cells
after downregulation of c-MYC. Identical to the KRASG12D-driven tumor model, ablation of cMYC led to a compensatory upregulation of IGF-1R/AKT signaling and a significant increase in
the expression of total and phosphorylated XIAP protein. Collectively, results from RNA-Seq
combined with in vitro and in vivo analysis strongly confirmed that IGF-1R/AKT signaling was
upregulated as a compensatory response to c-MYC downregulation.

IGF-1R/AKT pathway inhibition in residual cancer cells delays tumor recurrence in cMYC induced pancreatic cancer model
Identical to our KRASG12D-driven pancreatic tumor model, we observed a clear deregulation of
the IGF-1R pathway in residual cancer cells in c-MYC-induced tumor model. Therefore, in order
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to experimentally address the potential role of the IGF-1R pathway for the survival of residual cMYC-induced cancer cells, we treated the residual tumor bearing mice with Linsitinib for 5 days.
As expected, we observed a dramatic reduction of phosphorylated IGF-1R along with
phosphorylated AKT upon treatment with the inhibitor. This reduction in phospho-IGF-1R and
phospho-AKT was complemented with a significant increase in tumor cell death, which was
reflected by a substantial increase in the level of cleaved CASPASE-3 (Figure 3.28A and B).
More interestingly, similar to residual tumor cells treated with the inhibitor in the KRASG12Dinduced tumor model, treatment of the regressed tumor in the c-MYC induced model also elicited
a dramatic increase in the total IGF1 receptor (IGF1R) level in parallel with total AKT (Figure
3.29C), further emphasizing the importance of the role of IGF-1R/PI3K/AKT signaling in the
survival of pancreatic cancer cells in the absence of a tumor driving oncogene. Linsitinib
significantly delayed the tumor growth and relapse in tumor-bearing mice, which was indicated
by reduced tumor size and delay in tumor growth in comparison to control treated mice (Figure
3.29A and B). Collectively, our findings strongly highlight the possibility of the IGF-1R
signaling pathway as an appropriate therapeutic target for the prevention or delaying of pancreatic
tumor recurrence in c-MYC induced tumors.

Targeted downregulation of KRAS in human pancreatic cancer cells with KRAS mutation
results in compensatory upregulation of IGF-1R/AKT signaling
We successfully demonstrated the IGF-1R/AKT pathway mediated survival of pancreatic cancer
cells in two independent mouse models. However, to take a step further and assess the importance
of our findings in human disease, we selected 2 different but well-characterized human pancreatic
cancer cell lines harboring mutations in KRAS, namely AsPC-1 and MIA PaCa-2 and tested the
consequences of the down-regulation of KRAS. An inducible knockdown of KRAS in both AsPC1 and MIA PaCa-2 cells did not have any discernible phenotypic effect from a short-term (48
hour) induction of shKRAS, however KRAS knockdown for longer duration (7 days) resulted in
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significant death of cancer cells. A few cancer cells were able to survive the KRAS
downregulation with decreased proliferation and an obvious change in their morphology (Figure
3.30A). Furthermore, an assessment of molecular alteration in these surviving cancer cells
showed a striking similarity to that of the residual cancer cells in KRASG12D-induced pancreatic
cancer cells from mice in vivo. Both human pancreatic cancer cell lines that were tested showed
significant upregulation of IGF-1R signaling with increased levels of phosphorylated BAD and
BIM. Specifically, AsPC-1 cells also showed an increase in total and phosphorylated XIAP, very
similar to our two different mouse tumor models (Figure 3.30B).
Next, to study the effects of KRAS ablation in vivo, a pooled population of AsPC-1 cells
was subcutaneously injected into athymic nude mice that were then treated with Dox for 2 weeks
following a successful engraftment and identification of palpable tumors (Figure 3.31A). After
Dox treatment, the downregulation of KRAS expression resulted in an arrest in cancer cell
growth and a slight reduction in tumor size in the majority of recipients. Biochemical analysis
also showed the expected upregulation in IGF-1R/AKT signaling and elevated levels of total and
phosphorylated XIAP in tumors from Dox-treated mice as compared to tumors from untreated
animals (Figure 3.31B). The absence of a more substantial regression of tumors associated with
true cancer cell dormancy in the xenograft model might likely be a consequence of selective
mechanisms by which cancer cells were able to bypass the RNA interference to restore
expression of KRAS. These striking observations in human pancreatic cancer cell lines in vitro
and in vivo highlighted that the compensatory upregulation of IGF-1R signaling is a common
mechanism for survival during the ablation of oncogenic signals.

Activation of IGF-1R signaling is a consequence of IGF1 autocrine signaling in both mouse
and human pancreatic cancer cells lacking conditional KRAS expression
We identified and validated the compensatory upregulation of IGF-1R signaling in residual
cancer cells upon the conditional downregulation of tumor driving oncogenes in mouse models as
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well as in human cancer cell lines. Next, to determine the source of the ligand, IGF1, for the
tumor cell specific activation of IGF-1R, we first performed IHC stainings on tissue sections from
bulk and residual tumors from both the KRASG12D and c-MYC-induced mouse models for
pancreatic cancer. A closer examination of these sections revealed a very low expression of IGF1
in tumor cells as well as stroma in bulk tumors. In contrast, we observed a stronger IGF1 staining
specifically in residual cancer cells in comparison to bulk tumors in both reversible cancer
models, suggesting that these observations were likely not due to a contamination of the dormant
cancer cells samples with stromal cells (Figure 3.32A). To ascertain the tumor cell specific
expression of the Igf1, we next performed a direct comparison of the Igf1 transcript by
quantitative RT-PCR in Dox untreated and treated pure cultured-cancer cells generated from both
KRASG12D and c-MYC-induced pancreatic cancers. Interestingly, we detected a significant
increase in the transcriptional upregulation of Igf1 in all tested cancer cells in response to the
conditional downregulation of oncogenic KRAS or exogenous c-MYC (Figure 3.32B). We also
validated these observations in the two different human pancreatic cancer cell lines following a
ligand-induced knockdown of KRAS (Figure 3.32C). Interestingly, the more substantial
transcriptional increase in IGF1 expression in AsPC-1 cells compared to MIA PaCa-2 cells was
directly proportional to the degree in IGF-1R phosphorylation and activation of AKT (Figure
3.30B). In summary, the combined results from the immunostaining of the tumor cells as well as
quantitative RT-PCR experiments of cultured cancer cells strongly shows that the increase in
IGF-1R signaling in cells that conditionally lack the primary oncogenic drivers (i.e., KRASG12D or
c-MYC) is a result of a cell-intrinsic upregulation of its ligand and the establishment of an
autocrine signaling loop (Figure 3.33).
Figure 3.1. Schematic of the Cre/loxP-dependent, tetracycline responsive, reversible
pancreatic tumor model: Generation of a genetically engineered mouse model that permit a
temporally and spatially controlled expression of oncogenic KRAS (KRASG12D) in a doxycycline
(Dox)-repressible manner (TET-OFF). The Pdx1 promoter facilitates the expression of Cre-
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recombinase in pancreatic progenitor cells during embryonic development, which in turn results
in the deletion of the loxP-flanked, translational stop sequence from CAG-lox-βgeo-lox-tTA
transgene. This in turn results in transcription of the tetracycline transactivator (tTA). The tTA
transactivator binds to the tetracycline-responsive operator/promoter (TetO), which drives the
expression genes under the control of this promoter (KRASG12D and luciferase) in mice.
Administration of doxycycline to the mice carrying all these transgenes results in the inhibition of
tTA binding to the TetO promoter resulting in the repression of expression of oncogenic KRAS
(KRASG12D) and luciferase.
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Figure 3.1.
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Figure. 3.2 Characterization of early precursor ductal lesions (PanINs) in mouse pancreas:
(A) H&E-stained section showing early low-grade PanIN (PanIN1) lesion in pancreas induced by
pancreas-specific expression of oncogenic KRAS (KRASG12D) in transgenic mice. (B) Preneoplastic lesions showing ductal characteristics validated by expression of ductal markersCK19 (red) and MUC1 (green). (C) Pre-neoplastic ductal lesions (CK19+, red) showing activated
RAS signaling (phosphoMAPK+, green). (D) Pre-neoplastic lesion with increased proliferation
indicated by Ki67-positivity (red, nuclear). Slides were counter-stained with DAPI (nucleus).
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Figure 3.2.
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Figure 3.3. Reversal of pancreatic pre-neoplastic ductal lesions occur upon downregulation
of oncogenic KRAS by administration of Doxycycline: (A) Western blot analysis of phosphoERK levels in pancreas in the presence (-Dox) or absence (+Dox) of mutant KRAS (KRASG12D),
after 3 months of age when mice have confirmed pre-neoplastic lesions. Dox represents
Doxycycline. NP represents wild-type pancreas. (B) Quantification of phospho-ERK1/2 in
normal (NP), pre-neoplastic (-Dox) and Dox-treated (+Dox) pre-neoplastic pancreas. (C)
Histological sections showing early PanIN lesions within the pancreas of 3-month-old transgenic
mice expressing oncogenic KRAS in pancreas (-Dox). Images on the right panel represent the
near-completely regressed PanIN lesions from experimental transgenic animals, which were
treated with Doxycline (+Dox) for 7 days at 3 months of age once the PanIN lesions were
formed. Lower panel shows the Ki-67 positive cells in PanIN lesions before (-Dox) and after
treatment (+Dox). Bars represent 50um (A).
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Figure 3.4. Kaplan-Meier survival plot: Kaplan-Meier overall survival analysis of mice with
indicated genotypes. Cohort size of each genotype is indicated in parentheses.
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Figure 3.4.
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Figure 3.5. Characterization of pancreatic cancers induced by expression of oncogenic
KRAS in pancreas: (A) H&E stained-section from a primary tumor from a Kras* Cdkn2a mutant
mouse showing invasive ductal adenocarcinoma. (B) Increased phospho-MAPK (green) co-stained
with CK-19 (red) indicate ductal tumor with activated RAS-MAPK pathway. (C) Ductal tumor
(MUC1+ve; green) showing increased proliferation indicated by very high nuclear Ki-67 (red)
positivity. Nucleus is counterstained with DAPI (blue). (D) PDAC showing increased desmoplasia
indicated by increased activated fibroblasts (α-SMA+ve; red) surrounding the tumor cells
(GFP+ve; green). Immunohistochemical staining for (E) MUC5AC, and (F) phospho-STAT3
(Y705). Scale represents 50um.
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Figure 3.5.
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Figure 3.6. Expression of oncogenic KRAS in pancreas with concomitant loss of Cdkn2a
tumor suppressor gene induces highly metastatic ductal adenocarcinoma: H&E-stained
histological sections in the left panel represent pancreatic tumor metastasis at indicated organs.
Immunofluorescence stained sections in the right panels show the GFP labeled (green) metastatic
tumor cells within the serial section represented on its immediate left. Nuclei are stained with
DAPI. The immunofluorescence staining was done on the serially sectioned tissues. Table shows
the relative incidence of tumor metastasis to the indicated organs. Bar represents 50 µm.
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Figure 3.7. Pancreatic tumors undergo loss of heterozygosity at Cdkn2a (p19Arf) during
progression in mouse model: Western blot analysis of primary pancreatic tumors derived from
Kras* Cdkn2a+/- (Cdkn2a+/-) and Kras* Cdkn2a-/- (Cdkn2a-/-) mice show loss of heterozygosity of
the Cdkn2a (p19Arf) allele in heterozygotes, which are indicated by a complete loss of the p19ARF
band. Trp53-/- MEF represents p53 tumor suppressor knockout MEFs, which serves as positive
control for p19ARF. NP represents wild-type normal pancreas. Kras* Cdkn2a-/- serves as negative
control for p19ARF. The loss of p19ARF is indirectly reflected on a significantly increased level of
MDM2 and complete absence of the tumor suppressor p53 protein in both Kras* Cdkn2a+/- and
Kras* Cdkn2a-/- tumors.
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Figure 3.7.
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Figure 3.8. Regression of primary ductal adenocarcinoma in transgenic mice in response to
downregulation of oncogenic KRAS: Top: H&E stained sections. Middle: IHC for phosphoERK1/2. Bottom: IHC for Ki67 in sections of primary pancreatic tumors from Kras*/Cdkn2a+/mice in the absence (-Dox) or presence (+Dox) of Doxycycline for 14 days. Bar represents 50
µm.
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Figure 3.8.
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Figure 3.9. Schematics of experimental approach for the detection, identification and
assessment of residual cancer cells in mice: Our model implements a novel approach of
orthotopic transplantation of genetically (GFP) labeled cancer cells from transgenic mice into the
pancreas of a wild-type recipient for the easy detection of GFP-labeled cancer cells in a wild-type
background.
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Figure 3.9.
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Figure 3.10. Regression of invasive pancreatic cancer in response to oncogenic KRAS
ablation: (A) Bioluminescence imaging on orthotopically transplanted secondary tumor-bearing
mice before (left) and after (right) 7 days of Dox-treatment. Image shows the complete
macroscopic regression (right) of fully developed orthotopically transplanted pancreatic tumors
upon downregulation of oncogenic KRAS by treating tumor-bearing mice (left) for 7 days with
doxycycline. Complete downregulation of oncogenic KRAS is indirectly demonstrated by the
absence of the tetracycline responsive luciferase signal in Dox-treated mice (bottom-right). (B)
Comparison of tumor growth of orthotopically transplanted secondary pancreatic tumors in
control (-Dox; red lines) and Dox-treated (+Dox; black lines). (C) Western blot image showing
the regression of tumors caused by downregulation of Kras signaling indicated by dramatic
decrease in phospho-ERK signal in 2 and 3-day Dox-treated pancreatic tumor tissues.
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Figure 3.10.
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Figure 3.11. Pancreatic cancer cells undergo apoptotic cell death in response to oncogenic
KRAS ablation: Immunohistochemical staining of cleaved CASPASE-3 (cCASP-3) in
orthotopically transplanted pancreatic tumors prior to Dox treatment (A), after 2 days (B) and 7
days of Dox (C) treatment. T= Tumor; N= Normal pancreas. Bar represents 50 µm.
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Figure 3.11.
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Figure 3.12. Residual cancer cells can facilitate tumor relapse on oncogenic KRAS reexpression: (A) Big palpable pancreatic tumor completely shrunk to non-palpable state as early
as one week after Doxycline treatment and remained regressed for as long as 8 weeks of Dox
treatment. Tumors swiftly reappeared after withdrawal of Dox. (B) GFP expressing tumor cells in
the orthotopically transplanted pancreatic tumor before (lower left) and after (lower right) 4
weeks of Dox treatment. Upper panel shows the corresponding bright-field image of respective
GFP image in lower panel. (C) Top: Hematoxylin and Eosin stained sections. Bottom:
Immunofluorescence staining for GFP (green) phospho-ERK1/2 (red), in the pancreatic tissue
sections before (-Dox) and after (+Dox) 4 weeks of Dox treatment. Nuclei are counter-stained
with DAPI. Scale bar represents 1cm (B) and 100um (C).
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Figure 3.13. Residual cancer cells remain quiescent upon oncogenic KRAS ablation: (A)
Immunofluorescence staining with Ki67 (red) and GFP (green) in pancreatic tissue sections from
unregressed, bulk (-Dox) and completely regressed, residual (+Dox) tumor. (B) Quantification of
proliferating tumor cells (GFP+/Ki67+) in bulk (-Dox) and residual (+Dox) tumors. (C)
Immunofluorescence co-staining for TUNEL (green) and GFP (red) in the bulk (-Dox) and
residual (+Dox) tumor. (D) Quantification of tumor cells undergoing cell death in bulk and
residual tumors. * represents P<0.05.
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Figure 3.13.
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Figure 3.14. High-resolution display of Kras gene expression in KRAS-driven pancreatic
tumors: (A) IGV view of the Kras transcripts in bulk (-Dox) and residual (+Dox) tumors. (B)
Quantitative display of Kras transcripts in (A).
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Figure 3.14.
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Figure 3.15. Bioinformatics assisted identification of enriched gene sets and pathways in
KRASG12D-induced pancreatic tumors: (A) Gene set enrichment analysis (GSEA) performed on
transcriptomes from KRASG12D-expressing bulk (-Dox) and non-expressing regressed residual
(+Dox) pancreatic tumors identified a wide-array of cancer-associated gene-sets enriched in
KRASG12D-expressing tumors. (B) Heatmap showing a small set of genes that are significantly
altered in bulk (-Dox) and residual (+Dox) tumors.
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Figure 3.15.
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Figure 3.16. Identification of enrichment of IGF1 pathway in KRASG12D non-expressing
residual pancreatic tumors using Bioinformatics approach. (A) List of the top 10 highly
enriched gene sets identified by GSEA analysis performed on transcriptomes from KRASG12Dexpressing (-Dox) and non-expressing regressed (+Dox) pancreatic tumors identified a wide-array
of cancer-associated gene-sets enriched in Kras-expressing tumors. (B) Enrichment plot of the
IGF1 pathway in residual cancer cells (+Dox) as compared to KRASG12D-expressing tumors (Dox). (C) Heatmap showing a set of candidate genes from the IGF1 pathway that are
significantly altered in bulk (-Dox) and regressed (+Dox) tumors. (D) Integrative Genomics
Viewer (IGV) visualization of the Igf1 transcript abundance in bulk (-Dox) and residual (+Dox)
tumors. (E) Quantitative comparison of transcript abundance in bulk (-Dox) and residual (+Dox)
tumors (n=3). ** represents P<0.01.
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Figure 3.16.
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Figure 3.17. IGF1 receptor signaling is upregulated in residual cancer cells:
Immunohistochemical staining for the detection of activated IGF1 receptor (phospho-IGF-1R)
expression in bulk (-Dox) and residual (+Dox) tumor cells. Bar represents 50 µm.
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Figure 3.17.
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Figure 3.18. Biochemical validation of the increase in IGF-1R/AKT signaling in residual
cancer cells following KRASG12D extinction. (A) Western blot analysis of bulk (-Dox) and
residual (+Dox) tumors for analysis of activated IGF-1R (phospho-IGF-1R) and its downstream
effectors responsible for cell survival. Residual tumor cells show increased phosphorylated IGF1R and AKT along with AKT substrates: BAD, BIM and XIAP. Triplicates of each sample type
(-Dox and +Dox) were used for comparison. (B) Image-J quantification of protein bands for total
XIAP and phosphorylated IGF-1R, AKT, BAD, BIM and XIAP in immunoblot above (A). Data
are represented as Mean ± SEM. * represents P<0.05.
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Figure 3.19. Generation of mouse primary pancreatic cancer cell lines with doxycyclineregulatable KRASG12D expression: (A) Bioluminescence imaging in two independent primary
cancer cell lines generated from Kras*, Cdkn2a-/- mice showing complete absence of luciferase
activity after 48 hours of Dox treatment (+Dox) compared to control (-Dox). (B) Western blot
analysis demonstrating both KRAS and phospho-ERK1/2 expression is tightly controlled by
doxycycline treatment in 2 different cell lines. (C) Image shows change in morphology from
floating fibroblast-like (-Dox) to flattened epithelial-like (+Dox) cells within 48 hours of Dox
treatment.
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Figure 3.19.
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Figure 3.20. Cell intrinsic activation of IGF-1R/AKT signaling in cancer cells following longterm ablation of KRASG12D in vitro. Immunoblot analysis performed on 2 independent tumor cell
lines after treatment with Dox for variable time points (0, 2 and 7 days) show activation of IGF-1R
pathway.
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Figure 3.20.
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Figure 3.21. Experimental scheme for the treatment of residual cancer cells with IGF-1R
inhibitor in combination with doxycycline in vivo. A GFP-labeled tumor fragment from
transgenic mouse was orthotopically transplanted into the pancreas of a wild-type recipient and
was allowed to grow to a palpable size of approximately 10mm in diameter. The tumor-bearing
mouse was treated with Dox for 2 weeks until the tumor completely regressed, followed by oral
administration of vehicle or IGF-1R inhibitor (Linsitinib/OSI-906) for 5 consecutive days along
with Dox treatment. After treatment, KRASG12D was re-induced (-Dox) and mice were monitored
for tumor relapse.
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Figure 3.21.
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Figure 3.22. Combined inhibition of KRASG12D and IGF-1R signaling results in the
induction of apoptosis mediated cell death in residual cancer cells. Western blot analysis of
IGF-1R inhibitor (Linsitinib) and vehicle treated (2 and 3 days) regressed tumors (+Dox) for
analysis of induction of apoptosis indicated by the increased apoptosis marker, cleaved PARP
(cPARP). Immunoblot shows a decrease in both phospho-IGF-1R and phospho-AKT upon
Linsitinib treatment.
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Figure 3.22.
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Figure 3.23. Combined inhibition of KRASG12D and IGF-1R signaling in residual cancer
cells delays tumor recurrence: (A) FACS analysis of regressed tumors (+Dox) after 2 days of
IGF-1R inhibitor (Linsitinib) shows remarkably increased apoptosis indicated by an increase in
AnnexinV+ (right), as compared to vehicle treated tumor samples (Control). (B) Quantitative
representation of percent apoptotic cells in (A). (C) Tumor growth curves comparing cancer
recurrence between controls and Linsitinib treated tumor-bearing mice following reactivation of
mutant KRAS. (D) Kaplan-Meier survival plot of survival of residual tumor bearing mice after
treatment with vehicle (Control) or inhibitor (Linsitinib) along with Dox. Data are represented as
mean ± SEM. * and ** indicate P value <0.05 and 0.01 respectively.

131

Figure 3.23.
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Figure 3.24. Wild-type IGF-1 receptor partially rescues tumor regression upon ablation of
oncogenic KRAS: (A) Immunoblot to validate the elevated levels of exogenous IGF-1R in two
mouse pancreatic cancer cell lines that conditionally express mutant KRAS. (B) Tumor size
comparison in control and IGF-1R overexpressing tumors after KRAS ablation for 3 weeks. (C)
Bioluminescence imaging to show the co-repression of luciferase in mice with minimal residual
disease following the Dox-mediated ablation of mutant KRAS. (D) Immunoblot to validate the
sustained expression of exogenous IGF-1R in dormant cancer cells following downregulation of
mutant KRAS.
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Figure 3.24.
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Figure 3.25. Bioinformatics assisted identification of enriched gene sets and pathways in
conditional c-MYC-driven pancreatic tumors. (A) Lists of top the 10 gene sets identified by
GSEA analysis performed on transcriptomes from c-MYC-expressing bulk (-Dox) and nonexpressing residual (+Dox) pancreatic cancer cells. Gene sets in the list highlighted in red
indicate gene sets with a known role in cancer. (B) Enrichment plot of a few significantly
enriched candidate gene sets in c-MYC-driven pancreatic tumors. (C) Heatmap showing a small
set of genes that are significantly altered in c-MYC-expressing, bulk (-Dox) and regressed
(+Dox) tumors.
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Figure 3.25.
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Figure 3.26. IGF1 receptor signaling is upregulated in residual cancer cells in a tumor
model expressing c-MYC: (A) IGV view of Igf1 transcript abundance in RNA-Seq data from
bulk (-Dox) and residual (+Dox) tumors. (B) Quantitative representation of Igf1 transcript
abundance in bulk (-Dox) and residual (+Dox) cancer cells (n=2). Data are represented after
normalization. (C) IHC staining for phospho-IGF-1R (Y1161) expression in bulk (-Dox) and
residual cancer cells (+Dox). Bar represents 50 µm.
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Figure 3.26.
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Figure 3.27. Validation of an increase in IGF-1R/Akt signaling in residual cancer cells
following c-MYC ablation: (A) Western blot analysis of bulk (-Dox) and regressed (+Dox)
tumors for analysis of activated IGF-1R (pIGF-1R) and AKT (pAKT). Residual tumor cells show
increased phosphorylated IGF-1R and AKT along with the phosphorylation of the AKT substrate:
XIAP. Residual tumors also have an increased level of PDGFRβ. Triplicates of each sample types
(-Dox and +Dox) were used for comparison. Image-J quantification of protein bands for pIGF1R, pAKT and pXIAP in immunoblot (right). (B) Validation of cell autonomous upregulation of
IGF-1R signaling by immunoblotting in cultured cell lines generated from c-MYC induced
pancreatic tumors. Data are represented as mean ± SEM. * indicate P value <0.05.
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Figure 3.27.
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Figure 3.28. Combined inhibition of c-MYC and IGF-1R signaling results in induction of
apoptosis mediated cell death in residual cancer cells: (A) Western blot analysis of IGF-1R
inhibitor (Linsitinib) and vehicle (control) treated (3 days) regressed tumors (+Dox; c-MYC
negative) for analysis of induction of apoptosis indicated by the increased apoptosis marker,
cleaved CASPASE-3 (cCASP-3). Immunoblot shows a decrease in both phospho-IGF-1R and
phospho-AKT upon Linsitinib treatment. Compensatory upregulation of total IGF-1R and AKT
can be clearly seen. (B) Image-J quantification of protein bands for pIGF-1R, pAKT and cCASP3 in immunoblot above (A). (C) Image-J quantification of protein bands for total Igf-1R and Akt
in immunoblot above (A). Data are represented as mean ± SEM. *, **, *** and NS indicate P
value <0.05, <0.01, <0.005 and >0.05 respectively.
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Figure 3.29. Combined inhibition of c-MYC and IGF-1R signaling results in reduced tumor
growth and delayed tumor relapse: (A) Direct comparison of vehicle (control) and IGF-1R
inhibitor (Linsitinib) treated (5 consecutive days) regressed tumors (+Dox; c-MYC negative), 4weeks after withdrawal of Dox and inhibitor in vivo. (B) Tumor growth after tumor recurrence in
DMSO or Linsitinib treated residual tumors (+Dox; c-MYC negative) 4-weeks after withdrawal
of Dox and inhibitor in vivo. Data are represented as mean ± SEM. * indicate P <0.05.
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Figure 3.30. IGF-1R/PI3K/Akt signaling is increased upon conditional downregulation of
KRAS in KRAS mutant human pancreatic cancer cells in vitro: (A) Bright-field images of
cultured AsPC-1 and MIA PaCa-2 cells before (-Dox) and after seven days of doxycyclineinduced expression (+Dox) of a KRAS-specific shRNA. Quantitative representation of dead cells
before (-Dox) and after (+Dox) Dox treatment is displayed on the right. (B) Immunoblot showing
deregulation of the IGF-1R/AKT pathway in surviving cancer cells following long-term
downregulation of KRAS (7 days Dox treatment).
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Figure 3.30.
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Figure 3.31. IGF-1R/AKT signaling is increased upon conditional downregulation of KRAS
in human pancreatic cancer cells in vivo: (A) Tumor growth response of human pancreatic
cancer cell (AsPC-1) in the absence or presence of Dox in vivo. (B) Immunoblot demonstrating
the upregulation of the IGF1R/AKT pathway in response to long-term downregulation of KRAS
in human pancreatic cancer cells in vivo.
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Figure 3.31.

148

Figure 3.32. Upregulation of IGF1 is a cancer cell-intrinsic mechanism in the absence of
mutant KRAS or c-MYC oncogenic drivers: (A) Immunohistochemical staining of IGF1 in
bulk and residual cancer cells in KRASG12D (top) and c-MYC-induced (bottom) tumors. (B) qRTPCR analysis of Igf1 expression before (-Dox) and after (+Dox) 7 days of Dox treatment in
KRASG12D and c-MYC-induced pancreatic cancer cells, and, (C) human pancreatic cancer cells.
Scale represents 50 µm.
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Figure 3.33. Simplified display of the mechanism of cancer cell dormancy in the absence of
mutant KRAS and/or c-MYC expression. Figure on the left shows the predominant signaling
network in the presence of mutant KRAS or c-MYC in bulk tumors. Figure on the right
represents the predominant signaling network activated in the residual cancer cells in the absence
of driver oncogenes. In the absence of either of c-MYC or mutant KRAS, pancreatic cancer cells
activate IGF-1R/AKT signaling for survival via autocrine expression of IGF1 ligands.
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Figure 3.33.
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Chapter 4: Discussion*
*A part of this chapter is generated with the collaborative effort of Rajbhandari N, Lin WC,
Wehde B, Triplett AA, and Wagner KU, and has been submitted for publication under the title:
Autocrine IGF1 signaling mediates pancreatic tumor cell dormancy in the absence of
oncogenic drivers.
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Pancreatic cancer is a disease with a very poor prognosis, which currently stands as the fourth
leading cause of the cancer related deaths in the United States. This dismal prognosis of
pancreatic cancer stresses the urgent need for the development of targeted therapies to more
effectively treat this malignancy. Due to the very frequent occurrence of gain-of-function
mutations within the KRAS gene in PDAC (Hruban et al., 2000), and its role as a key regulator of
pancreatic cancer initiation in animal models (Aguirre et al., 2003; Hingorani et al., 2003), this
constitutively active GTPase is considered a rational therapeutic target. The concept of “oncogene
addiction” of cancer cells and the dependence of lung and breast cancer cells upon oncogenic
KRAS in vivo, strongly argues in favor this idea (Fisher et al., 2001; Podsypanina et al., 2008).
Despite the evidence from other tumors and widespread acknowledgement of oncogenic KRAS
as a potential therapeutic target for the treatment of pancreatic cancer, there was no sufficient
evidence in support of this idea prior to our work. Using KRASG12D driven reversible PDAC
models, our group and others (Collins et al., 2012a; Collins et al., 2012b; Ying et al., 2012) now
show that oncogenic KRAS is not only required for the initiation but it is equally important for
the maintenance of PDAC at primary and metastatic sites. These findings provide a strong
rationale for the use of targeted therapies to primary and metastatic pancreatic ductal
adenocarcinoma.
Despite the complete macroscopic regression of advanced PDAC upon ablation of
oncogenic KRAS, the persistent presence of a few residual cancer cells in the pancreas of mice
along with the swift recurrence of the disease following reactivation of the oncogenic driver
indicate that some cancer cells or advanced preneoplastic lesions were still present in the pancreas
following the downregulation of mutant KRAS. Using a cell-fate labeling method in an
alternative, reversible PDAC model that conditionally overexpresses c-MYC, our lab previously
demonstrated that a few pancreatic cancer cells that possess stem cell features were able to
survive in a quiescent state in the absence of the primary oncogenic driver (Lin et al., 2013). In
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this thesis, we demonstrated that residual tumor cells that conditionally lack oncogenic KRAS
show the characteristics of true cancer cell dormancy, in contrast to the previously defined “tumor
mass dormancy” where cancer cells exist in an equilibrium of cell division and cell death
(Aguirre-Ghiso, 2007). In fact, these residual cancer cells do not proliferate and they do not
undergo cell death. These residual cells can remain in a true quiescent state for prolonged
duration and serve as the cellular reservoir for a speedy recurrence of a clinically overt disease
upon receiving favorable cell intrinsic cues, such as the re-expression of the oncogenic driver. In
our current and previous work, we did not detect any large recurring tumors that reemerged in the
complete absence of the transforming oncogenes (i.e., mutant KRAS or c-MYC) when we
maintained diseased mice on Dox for an extended period. The effectiveness of the Dox-mediated
suppression of the transgenes in these mice was repeatedly monitored by the activity of a TetOdriven luciferase reporter transgene. These observations in our two PDAC models indirectly
negates the possibility of compensatory activation of any alternative molecular pathways such as
amplification of Yap1 that effectively mediate cancer recurrence in the complete absence of the
primary oncogenic drivers as reported recently (Kapoor et al., 2014). More importantly, the
analysis of RNA-Seq results did not reveal any differences in the expression of Yap1 mRNA
between bulk tumors and residual cancer cells in both animal models that conditionally express
mutant KRAS or c-MYC. This suggests that this transcriptional co-activator does not seem to
play a key role in cancer cell dormancy in our two models. At this point, we can only hypothesize
that a deficiency of wildtype p53 in the KRAS-associated PDAC model by Kapoor et al., as
opposed to the loss of Cdkn2a in our models, might be a factor responsible for the reported gainof-function of YAP1 during tumor recurrence in the complete absence of oncogenic KRAS.
While the collective findings of mutant KRAS and c-MYC-associated pancreatic cancer
models clearly support the rationale for the development of targeted therapies against these
oncogenic drivers, they also portend that cancer cell dormancy will remain a lingering challenge
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during the advent of targeted therapies for the treatment of PDAC. Regardless of subsequent
molecular events that may promote disease recurrence, it is equally, if not more, important to
understand the mechanisms that mediate cancer cell dormancy in an effort to eliminate residual
disease following first-line therapy. Surprisingly, we did not observe a significantly upregulated
expression of gene sets associated with mitochondrial and peroxisomal β-oxidation or the
electron transport chain when we performed GSEA on RNA-Seq data obtained from bulk and
residual cancer cells from either of the two different GEMM of pancreatic cancer. This was in
stark contrast to the previously published report based on a gene array-based transcriptome
analysis of cultured tumor spheres that were conditionally deficient in mutant KRAS (Viale et al.,
2014). This major difference in findings could possibly be explained in 2 ways: first, the
difference in the sample selection for transcriptome analysis, as they used tumor spheres grown in
vitro in contrast to the in vivo derived tumors in our study; and second, may be the use of Trp53
knockout model in their study, in contrast to the use of Cdkn2a knockout in our model. However,
we have identified the activation of autocrine IGF1 signaling and the downstream activation of
AKT as a common mechanism that promotes cancer cell survival and dormancy following the
specific ablation of the oncogenic drivers. Conversely, overexpression of wild-type IGF-1R was
sufficient to counteract the ablation of mutant KRAS in mice leading to more extensive residual
disease. We demonstrated that co-targeting mutant KRAS and IGF-1R reduces the number of
residual cancer cells and delays tumor recurrence. We also validated the importance of this
finding in human pancreatic cancer by demonstrating the compensatory upregulation of IGF1R/AKT signaling upon downregulation of KRAS in 2 independent human pancreatic cancer cell
lines harboring a KRAS mutation. Furthermore, our findings in the c-MYC-driven cancer model
presented in this work suggest that the autocrine activation of IGF-1R/AKT signaling in dormant
pancreatic cancer cells is not restricted to the RAS/RAF cascade and might not be exclusive to
targeted therapies. The role for IGF1 autocrine signaling has already been recognized as a
potential mechanism for prostate cancer cells to evade androgen deprivation therapy (Nickerson

156

et al., 2001), and a more recent report highlighted the significance of IGF1 in glioma stem cells
that are resistant to radiation (Osuka et al., 2013).
IGF-1R signaling has been previously reported to be crucial for neoplastic transformation
and survival of epithelial cells in the mammary gland and pancreas in response to the expression
of oncogenic mutants of KRAS and BRAF (Appleman et al., 2012; Klinakis et al., 2009). A more
direct association of enhanced IGF-1R and AKT signaling and the development of acquired drug
resistance following the targeted inhibition of BRAF have been demonstrated recently in human
melanoma and a corresponding mutant BRAF expressing mouse model (Perna et al., 2015;
Villanueva et al., 2010). In a more recent study, Lovly et al. also reported that co-targeting IGF1R enhances the antitumor effects of ALK inhibitors in certain human lung cancer types (Lovly et
al., 2014). However, the pharmacological inhibition of IGF-1R signaling was not fully sufficient
to eradicate all residual cancer cells in our KRAS and c-MYC-driven reversible PDAC models.
This might be best explained by heterogeneity in dormant pancreatic cancer cells, which was
demonstrated in our prior work based on differences in the expression levels of various stem cell
markers (Lin et al., 2013). It is also likely that a subset of these residual tumor cells also engages
in a compensatory increase in the activation of other receptor tyrosine kinases such as PDGFRB
and FGFR1, which seems to play a role in the recurrence of melanoma and lung cancers
following treatment with Vemurafenib (BRAF inhibitor) and Afatinib (EGFR inhibitor)
respectively (Azuma et al., 2014; Nazarian et al., 2010). Since we observed a robust coupregulation of PDGFRB on the transcriptional and protein level in dormant cancer cells of both
murine tumor models as well as human AsPC-1 cells in response to the shRNA-mediated
downregulation of KRAS, it might be reasonable to assess in future studies the combinatorial
effects of the inhibition of PDGFRB and IGF-1R for the eradication of minimal residual disease
following the ablation of the primary oncogenic drivers KRAS and c-MYC.
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Chapter 5: Summary
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The collective results of this dissertation, along with recently published work from other groups,
using GEMM reversible PDAC models clearly indicate that expression of mutant KRAS is not
only important for the initiation of pancreatic cancer, but also for the maintenance of advanced
PDACs. This establishes mutant KRAS as an suitable target for the treatment of major PDAC
types. Using a novel Dox-repressible PDAC model system, we have successfully demonstrated
that exogenous expression of mutant KRAS in mouse pancreatic progenitors is sufficient to
induce genuine classical PanIN precursor lesions, which progressed into invasive primary and
metastatic PDAC when oncogenic KRAS was expressed in the absence of the CDKN2A tumor
suppressor. Ablation of oncogenic KRAS in early primary pre-neoplastic lesion as well as in
invasive tumors in secondary recipient mice resulted in a reversal of neoplasia to a near normal
state by induction of cell death, suggesting that the tumor initiating oncogenic KRAS is equally
important for the progression and maintenance of pancreatic cancer. This observation from our
pancreatic cancer-model expressing mutant KRAS provides a sound rationale for the
development of targeted therapies against oncogenic KRAS (or RAS pathway) to treat early and
advanced stages of pancreatic cancer. In the second part of this thesis, using a genetic cell-fate
mapping technique (GFP-labeling) in combination with orthotopic transplantation of primary
tumors into wild-type recipients, I was able to show that despite the complete macroscopic
regression of the tumors upon KRAS deletion, a few cancer cells were able to survive and remain
as a residual disease for a prolonged period of time. These dormant cancer cells possessed a very
high ability for tumor remission upon the re-induction of oncogene. Following the isolation and
transcriptome analysis of in vivo derived bulk tumor cells and dormant cancer cells that survived
the ablation of oncogenic KRAS, we were able to demonstrate that residual cancer cells have
significantly increased expression of IGF1, which in turn activated IGF-1R/AKT signaling as a
cell-intrinsic mechanism for their survival in KRASG12D-induced tumors. We have experimentally
validated the importance of this signaling pathway in cancer cell survival in the absence of
oncogenic KRAS. In comparison to control mice, we observed significantly slower tumor growth
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and delayed tumor relapse resulting in longer survival of the tumor bearing mice though a
combination of IGF-1R/AKT pathway inhibition and ablation of oncogenic KRAS.
In conclusion, our current and the previous studies provide a sound rationale for the
development of targeted therapies against oncogenic drivers like oncogenic KRAS and c-MYC,
to treat early and advanced stages of pancreatic cancer. However, our study also highlights the
importance for the development of an adjuvant therapeutic strategy targeting this IGF-1R/AKT
pathway in addition to oncogenic drivers to effectively eradicate residual cancer cells and to
prevent pancreatic cancer recurrence.
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6.1. Elucidate the role of various receptor tyrosine kinases like PDGFRΒ, FGFR1 and
FGFR2 in pancreatic cancer-cell survival in the absence of oncogenic KRAS and c-MYC
Using 2 different GEMMs of PDAC and human pancreatic cancer cell lines, we demonstrated
that pancreatic cancer cells could survive in the absence of oncogenic drivers by upregulation of
AKT signaling via upstream activation of the IGF-1 receptor. Besides the upregulation of Igf1
expression in residual cancer cells in both KRASG12D and c-MYC-induced tumors models along
with human AsPC-1 cells, we also observed a significant upregulation of various other RTKs
(PDGFRβ, FGFR1 and FGFR2) at the transcript and protein level, as shown in chapter 3 (Figure
6.1). Interestingly, all of these abovementioned RTKs can independently and efficiently sustain
PI3K/AKT pathway activation, and have been previously reported to be responsible for targeted
therapy resistance in many human tumors like colorectal cancer, lung cancer, melanoma and
glioblastoma (Azuma et al., 2014; Holohan et al., 2013; Liu et al., 2015; Nazarian et al., 2010;
Ware et al., 2013; Weigel et al., 2013). Based on this notion, experimental determination of the
combinatorial effects of the inhibition of these RTKs along with IGF-1R for the eradication of
minimal residual disease following the ablation of the primary oncogenic drivers, KRAS and cMYC is warranted in the future. Because of the lack of appropriate model systems for the
reversible expression of oncogenic KRAS or c-MYC combined with temporal and conditional
deletion of any gene in advanced tumors, it is currently impossible at this moment to directly
address the role of any of the above-mentioned RTKs in residual cancer cells using a genetic
approach in vivo. Therefore, the most logical approach to address the role of each of the
overexpressed RTKs would be to utilize specific RTK inhibitors alone or in combination with an
IGF-1R inhibitor to ablate receptor signaling in residual cancer (Figure 3.21). The outcome of this
study will help us understand the independent and combined role of these RTKs along with IGF1R to up-regulate AKT signaling and cancer cell dormancy.
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Figure 6.1. High-resolution display of various RTK gene expressions in KRASG12D and cMYC-driven pancreatic tumors: (A) IGV view of the Pdgfrb, Fgfr1, and Fgfr2 transcripts in
bulk and residual tumors in both KRASG12D and (B) c-MYC-driven pancreatic models, which
were determined by RNA-Seq.

163

Figure 6.1.
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6.2. Elucidate the role of anti-apoptotic BCL2 family member BCL2A1 in pancreatic
cancer-cell survival during oncogenic KRAS ablation
Proteins involved in apoptosis regulation are of biological interest and many are attractive
therapeutic targets for the treatment of a variety of cancers. The members of BCL2 protein family
have drawn the most attention among many others. The BCL2 family proteins function in cell
death and survival decisions by regulating the process of mitochondrial outer membrane
permeabilization (MOMP) in apoptosis. The BCL2 family contains 3 main groups based on the
regions of BCL2-homology (BH) domains and functions: multi-domain antiapoptotic (BCL2,
BCL-XL, MCL1, BCL-W and BCL2A1), multi-domain proapoptotic (BAX, BAK) and BH3only proapoptotic (BAD, BID, BIM, BIK, PUMA, NOXA and BMF) (Certo et al., 2006).
Antiapoptotic members of the BCL2 family prevent cell death by preventing the MOMP and
cytochrome c release by counteracting the oligomerization of BAX and BAD, either by
sequestration of BH3-only proteins or by binding with BAX/BAK itself.

Although the

physiological and pathological roles of BCL2, MCL1 and BCL-XL have been extensively
studied, the function of BCL2A1 in apoptosis inhibition is less well known. This is mainly
because of its restricted expression in the hematopoietic compartment in mouse and human, along
with its widespread expression reported primarily in lymphoid malignancies (Vogler, 2012).
However, very high expression of BCL2A1 mRNA in human gastric and breast cancers imply its
possible role in solid tumors (Vogler, 2014). In fact, more direct association of BCL2A1 in solid
tumors have been recently reported by demonstration of acquired resistance to the BRAF
inhibitor by amplification of BCL2A1 in human melanoma (Haq et al., 2013).
In our current study, comparison of RNA-Seq data from bulk and residual tumors from
KRASG12D-induced cancers revealed a consistent and significantly higher expression of all 3
functional isoforms (Bcl2a1a, Bcl2a1b and Bcl2a1d) in the residual cancer cells following the
ablation of oncogenic KRAS (Figure 6.2A). This might imply a potential role of BCL2A1 in the
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survival of pancreatic cancer cells. Closer examination of transcriptomics data along with
biochemical analysis confirmed that BCL2A1 was the only antiapoptotic BCL2 family member
upregulated in residual cancer cells with the concomitant increase of numerous pro-apoptotic
BAD, BIM, BMF and PUMA (Figure 6.2B). We also showed that the BCL2A1 expression was
specific to the cancer cells in residual tumors rather than the immune cells or stromal cells (Figure
6.2C). BCL2A1 has been shown to bind with pro-apoptotic BH3-only proteins, BIM and PUMA
with the strongest affinity in comparison to any other BCL2 family protein (Certo et al., 2006).
Sequence

similarity

predicts

BCL2A1

(http://www.uniprot.org/uniprot/Q16548).

Based
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with
observation

BMF
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hypothesize that BCL2A1 prevents the killing of residual pancreatic cancer cells that are already
“primed for death” by interacting and preventing the proapoptotic proteins like BIM, BMF and
PUMA. It will be of considerable interest to determine if BCL2A1 has a role in cancer cell
survival and maintenance of dormancy, and to determine if inhibition of BCL2A1 results in
prevention of disease recurrence following the ablation of oncogenic KRAS. Early preliminary
results obtained from a very small cohort of mice strongly favor our hypothesis, indicating a very
important role of BCL2A1 in the survival of residual cancer cells after ablation of oncogenic
KRAS. Using a pharmacological approach to inhibit BCL2A1 in the residual tumors using a PanBCL2 inhibitor (Obatoclax) we observed a significant delay in the recurrence of pancreatic
tumors in comparison to the vehicle treated control mice after re-induction of oncogenic KRAS
(Figure 6.2D). However, it still remains to be tested if the delayed tumor recurrence is due to the
death of residual tumor cells from a specific antagonism of BCL2A1 or due to an off-target effect
of the inhibitor. To address this genetically, I have already made and characterized two BCL2A1
(pCMMP-2xMYC-BCL2A1-IRES-mRFP) overexpressing and isogenic control pancreatic cancer
cell lines from Kras* Cdkn2a mutant mice. Currently, I am in the process of testing the efficacy
of the exogenous BCL2A1 to rescue the viability of pancreatic cancer cells in vitro and in vivo
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after the abrogation of oncogenic KRAS. Further studies will be needed to confirm the role of
BCL2A1 in residual cancer cell survival in the absence of mutant KRAS.
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Figure 6.2. Anti-apoptotic BCL2A1 is highly upregulated in residual cancer cells in
oncogenic KRAS-induced pancreatic cancer model: IGV view of the Bcl2a1a, Bcl2a1b and
Bcl2a1d transcripts in bulk and residual tumors in KRASG12D-induced tumors. (B) Immunoblot
analysis showing deregulated expression of various pro-apoptotic BCL2 family members, along
with an increase in BCL2A1 as the only anti-apoptotic BCL2 family protein. (C) IHC stainings
shows increased and tumor cell specific staining of BCL2A1 in residual cancer cells. Scale
represents 100 µm (D) Tumor growth curves comparing cancer recurrence between controls and
pan-BCL2 inhibitor (Obatoclax) treated tumor-bearing mice following reactivation of mutant
KRAS.
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Figure 6.2.
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6.3. Investigate the role of E3 ubiquitin protein ligase XIAP in the survival of pancreatic
cancer cells during ablation of oncogenic drivers like oncogenic KRAS and c-MYC
Cells can undergo apoptotic cell death in two well defined, but distinct mechanisms: (1) the
extrinsic or death receptor pathway, and (2) the intrinsic or mitochondrial pathway (Elmore,
2007). Despite the difference in the mechanism of the initial activation of these 2 pathways, both
these pathways ultimately converge to a common pathway to activate downstream caspase
cascade to execute the programmed death of the cells. Caspases are normally expressed in an
inactive pro-enzyme form with little or no enzymatic activity in cells, but once activated they
activate other downstream pro-caspases, allowing initiation of a protease cascade. This
proteolytic cascade amplifies the apoptotic signaling pathway and thus leads to rapid cell death
(Salvesen and Duckett, 2002). Caspases have proteolytic activity and are able to cleave proteins
at aspartic acid residues with varying substrate specificity. Once caspases are initially activated,
cells are irreversibly committed towards the fate of death. To date, ten major caspases have been
identified and broadly categorized into initiators (caspase-2, 8, 9, 10), inflammatory caspases
(caspase-1, 4, 5) and executioners (caspase-3, 6, 7) (Elmore, 2007).
Although activities of caspases are kept in check by controlling their activation, another
equally important secondary mechanism of their regulation involves the direct inhibition of
nascent, active caspases. In mammalian cells, this is achieved by a group of specialized proteins
called ‘inhibitor of apoptosis’ (IAPs). XIAP (X-linked IAP) is one of the best-characterized
proteins of the IAP family, which is an E3 ubiquitin ligase with conserved baculoviral IAP repeat
(BIR) and RING domain. It is a potent inhibitor of cell death triggered by a range of apoptotic
stimuli. The antiapoptotic effect of XIAP is mainly conferred by its ability to suppress specific
caspases (caspase-3, 7 and 9) through direct binding and their subsequent proteasomal
degradation. Thus, XIAP functions at the post-mitochondrial level, in contrast to the antiapoptotic BCL2 family members, which function at pre-mitochondrial level, upstream of the
apoptosome, to prevent integration of the caspase-activating signal (Deveraux and Reed, 1999;
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Salvesen and Duckett, 2002; Vaux and Silke, 2005). Since we observed a consistent upregulation
the XIAP in residual cancer cells in both KRASG12D and c-MYC induced tumor models along
with human cancer cell line (AsPC-1) upon downregulation of oncogenic drivers, we hypothesize
that XIAP might play an important role in the post-mitochondrial mechanism of pancreatic cell
survival upon therapeutic targeting of tumor driving oncogenes. It will therefore be very
important to address the role of XIAP in mediating therapy resistance and tumor cell dormancy in
case of pancreatic cancer. Currently, I am attempting to test the role of XIAP in anti-apoptosis
experimentally by using both pharmacological and genetic approach in the same way I did for
addressing the role of IGF-1R signaling pathway in chapter 3. Further studies in the future will
address the role of XIAP in residual cancer cell survival in the absence of tumor drivers like
mutant KRAS and c-MYC.
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